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EDITORIAL 
APPROACHES TO 
SUBSTANCE ABUSE 
D rugs of abuse consist of those which are entrenched in our way of life (like alcohol and tobacco) and those which are illegal (like cocaine, heroin, cannabis, amphetamine, etc.). Current problems associated with drugs of 
abuse include failure to eradicate substance abuse, excessive morbidity and 
mortality consequent to substance abuse, and the financial burden of drug-related 
health problems to the health care system (see inset). 
In order to gain some idea of the current approach to problems associated with 
substance abuse, I spoke with Alan Ogborne, a senior scientist (programs and 
services evaluation, research department) at the Addiction Re earch Foundation 
(ARF) in London. Clearly, there are no hard fast solutions to the problems of 
substance abuse. The ARF recently outlined some objectives to be accomplished by 
the year 20001 • These objectives included reductions in alcohol use by 25%; cocaine 
and crack use by 50%; and alcohol-related traffic fatalities to 15% (from 50%). As 
well the ARF is aiming for a balanced, appropriate, and accessible treatmentservice 
system. Current programs designed to achieve these goals are aimed at reducing 
the demand for drugs, as opposed to the supply--supply reduction has proved 
very costly and very ineffective. 
Programs designed to reduce demand include those emphasizing health 
promotion and education (i.e. creating an awareness of the effects of drugs) and 
programs designed to treat people who require assistance and therapeutic 
intervention. According to Hans Embald, director of the World Health 
Organization (WHO) on substance abuse, strategies to reduce drug abuse should 
be based on recognition of political and economic realities of people's lives2• In the 
past, addictive drugs have been viewed as having mystical powers to not only 
induce "positive" psychologic and physiologic effects, but to siphon an 
individuals' ability to make a choice as well. The WHO recommends that 
programs to reduce drug abuse shouldn't focus only on the harmful and mystical 
properties of drugs thereby glamourizing them, but should challenge the drugs' 
"positive" effects and remove the glamour a sociated with them. These steps will 
allow education to progress. Programs developed within Ontario to discourage 
substance abuse include Drug Awareness Week, Server Intervention, R.I.D.E., Sober 
Driver, Just Say No, and Alcohol on Campus. 
Treatment facilities and programs exist which are more suitable to reduce 
demand in people who have developed dependencies or are likely to. The ARF has 
developed an early intervention program designed to help people who have 
drinking problems but are not yet dependent on alcohol. This approach has gained 
support because of a potentially high success rate, the low costs, and the prospect 
for preventing more serious problems. Programs also exist to help people with 
drug dependency. Programs in Ontario include Detoxification, which provide a safe, 
supervised setting for drug withdrawal; Assessment/Referral, which assess people 
with alcohol and other drug problems; Non-Residential, which provide treatment, 
rehabilitation, and/ or aftercare; Short-term Residential, which offer structure, 
intensive treatment and/ or rehabilitation for 40 or fewer days; and Long-term 
Residential, such as recovery homes and halfway houses. Treatment programs for 
tobacco addiction are usually offered by other organizations such as the Lung 
Association, the Canadian Cancer Society, and other commercial organizations. A 
number of programs now incorporate, alcohol, tobacco, and other drugs. 
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Some facts '·' : 
,. 1985 Ontario deaths related to drug use: 20,006 (30% of total); 13,375 deaths associated with tobacco, 
6,506 related to alcohol, and 125 related to illegal drugs. 
,. Leading cause of death < 35: accidents and violence (50% related to drinking); leading causes of death 35-64 
include lung cancer and chronic liver disease (heavily linked to alcohol and tobacco). 
,. Number of alcohol-related offenses in Ontario in 1990: 106,851; number of offenses related to illicit drugs 
was 25,532. 
,. Cannabis is the most freq uently used illicit drug; cocaine is used much less freq uently; crack use is rare. 
,. The number of alcohol and drug treatment programs in Ontario in 1988-89 was 217; most common drug 
problem in the treatment system: alcohol; percent change in the number of people treated in the addictions 
treatment system from 1979-89: + 102%. 
,. 1991-92 gov't revenue from tobacco tax: $1,028 M (2.5% of total); revenue from LCBO profits and liquor-
related sales: $1,158 M (2. 8% of total). 
,. Total health care costs to Ontario related to drug abuse is estimated at $5.5 B. 
,. Indicators of alcohol and dn.tg problems in Ontario suggest a recent decline. 
Mutual aid groups, such a Alcoholics Anonymous, the Betty Ford Center, 
Narco tics Anonymous, and Women for Sobriety also aim at helping people recover 
from addiction through social support. Finally, other people and facilities offering 
drug treatment include general and psychiatric hospitals, mental health clinics, 
counselling agencies, and probation and correctional services. 
Controversy undoubtedly exi ts as to the effectiveness of various programs. An 
article by Holder et al. analyzed different treatment facilities for alcoholism based 
on effectiveness, benefits, and costs. 3 Their results suggested that 
residential / milieu treatment programs (e.g. Betty Ford, AA) were by far the least 
worthwhile, whereas brief motivational counselling, self-control training, and 
social skills training were among the best treatment modalities. Apparently many 
reports regarding programs like Betty Ford tend to be based on testimonial 
evidence from "program graduates" and uncontrolled studies using "graduates" 
as subjects. As well enrolment in these programs is elective--applicants are chosen 
based on a willingness to seek aid and self-discipline. Many drug users don't have 
these characteristics. 
Certainly, problems associated with drug abuse and addiction are the focus of 
much effort and attention. Ultimately, the ideal aim of treatment facilities is 
complete abstinence. For many people reduction in use to a non-hazardous level is 
a more realistic goal. The battle against substance abuse is uphill, but current 
efforts suggest forward progress. 
Before closing, I would like to congratulate Ross and Shobhana, and the entire 
Journal Staff for a job well done. We've designed a new cover utilizing school 
colours and the new faculty ere t. We've also incorporated a new ection called 
Faculty News to promote the Journal as a communication medium for the Faculty 
of Medicine and the London Medical Community. A coordinated effort and 
informative articles have helped produce a very good issue! I would also like to 
welcome Dr. McMurtry as the new Dean of the Faculty of Medicine. On behalf of 
the Journal I wish him good fortune, and I hope that the school profits from his 
wisdom. 
1) ARF Report. Drugs In Ontario. 48 pp (1990). 
2) ARF Joumal21(5):1992. 
3) Holder H., et al. J. Stud. A1cohol.52:517-40 (1991). 
4) Ministry of Treasury and Economics. 1992 Ontario Budget. 115 pp. (1992). 
Q 
Jeffrey Politsky, 
Editor. 
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DEANS' CORNER 
T his marks the first effort toward what we hope will become a regular feature in the journal. You will note from the position of the 
apostrophe in the title that the column is not just for 
the Dean himself to communicate with you, but also 
w ill reflect issues, plans, projects, trial balloons, and 
the flotsam and jetsam that any of us in the Dean's 
o ffice might feel would be of interest to the 
readership. For those readers who have been away 
from Western for a while, you may be interested to 
know that the Dean's office is currently configured 
into six divisions. As a result, there are Assistant 
Deans for curriculum (David Hollomby), education 
(Bob Barr), clinical affairs Oirn Silcox), postgraduate 
education (Bessie Borwein), and continuing 
education (Keith Paton). Besides this, we have the 
Office of Health Sciences Education, better known 
by its acronym, "OHSED", directed by David Lloyd . 
We hope that future issues will provide a forum for 
each of them to speak to you. 
In this first column, it seemed timely to talk a 
bit about career selection. In high school, we used 
to refer to this as guidance, and, there is long 
tradition at that level of trying to help students to 
make informed academic decisions leading them to 
the career of their choice. Medical schools never 
went in much for that sort of thing, even though 
the decisions that medical graduates have had to 
make have been every bit as bewildering as those 
that faced them when they left high school. 
Students were left to lurch into their lifelong 
medical careers by good luck, intuition, or 
fate ... perhaps all three . Sometimes it worked; 
sometimes it didn't. 
Now that the rules for licensure have changed 
and internship is a thing of the past, the first post 
graduate year is already a streaming year which sets 
the student on the path to her or his ultimate 
practice pattern. This has meant that these men and 
women must be well informed about the vast array 
of career options open to them. This is no mean 
trick to achieve by the summer and fall of fourth 
year when they make their applications to post 
graduate programs and prioritize their submissions 
to C.I.M.S. Needless to say, this has generated a lot 
of anxiety amongst students. It seems as if they 
have barely been admitted to medicine before they 
must start searching around for the answers that 
they need in order to select the post graduate 
training that is right for them. As if undergraduate 
medicine wasn't stress enough already! 
Facu l ty Ne ws 
At Western, we have developed two new 
initiatives to help . The first is the Glaxo Pathway 
Evaluation Program. Sponsored by Glaxo Canada, 
thi s program is composed of three parts. In 
o v ember of third y ear, during a week long 
orientation to phase IV, workshops will be held in 
w hich we teach the class a methodology for making 
decisions and give the students a chance to practice 
it . At the workshop, we provide the important 
second component of the program. Each student 
w ill get a binder, really a compendium, which 
contains relevant information about every specialty 
practised in Canada, including Family Medicine. 
This book contains details of training programs plus 
a lot of practical information about income, lifestyle, 
practice pros and cons, etc. The final part of the 
program is to encourage students to use the 
forthcoming clerkship not only to learn about 
clinical medicine but also as a window on the 
various career options that they can take. As they 
s tart a block, they should identify the career 
questions that they want answered by the time they 
leav e the service. They are encouraged to ask 
res idents and consultants to talk about their 
p e rceptions about their career choice. In other 
words, the clerkship should be viewed as a career-
guidance experience as well as a content/ skill / 
attitude learning experience. 
To complement this program, we will be 
launching in the new year a career fair or career 
night program. (We haven't quite settled on the 
format yet.) This will be targeted more at first and 
second year classes and will give an opportunity for 
representatives of the various specialities to meet 
the students, provide them with information about 
their own specialities and answer questions. 
Although some have referred to this as "recruiting", 
we are aiming for informality and a way to plant 
seeds in the minds of students who want 
information early in order to think a bit and 
perhaps focus their later inquiries. 
The result of all of this is that many physicians 
outside and inside the faculty will be subjected to a 
lot more questions from students about why they 
chose their areas of practice. I encourage all to take 
the time to respond honestly and thoughtfully. 
Now more than ever, our colleagues of the future 
are depending on us. 
Jim Silcox, M.D., 
Assistant Dean, 
Q 
Student Affairs & Undergraduate Studies. 
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HIPPOCRATIC COUNC I L 
NOTES 
Th~ 1992-93 Hippocratic Council, in association With the Meds Journal will be providing this column to improve communication betw een 
the Council, the student body, and the Faculty of 
Medic ine. It is our hope that this column will 
generate interest and new ideas for students both 
within the faculty at Western and at other Canadian 
Medical Schools. 
A special welcome to the Class of Meds ' 96, and 
a pat on the back to Meds '95 for a job well done 
during orientation. The Fanshawe Park Picnic was 
once again a great way to forget the summer! The 
recent Health Sciences Pub was a huge success -
thanks to Liisa Honey (Social VP) and all who vol-
unteered their time. 
So, what exactly does the Hippocratic Council 
do? A lot! For one, we keep Medical students in 
touch with issues by representation and participa-
tion on councils at Western ( eg. UMEC, Student 
Affairs, USC) and throughout the country (eg. 
CFMS, the Canadian Federation of Medical 
Students) . Last May, Katherine Wise (past VP-
Executive), Stephanie Windsor (past Community 
Relations Rep.) and Merrilee Brown (Secretary) at-
tended a conference on the evaluation of medical 
students held by the EFPO (Educating the Future 
Physicians of Ontario). Recently, Lesley Horton and 
Ambrose Au (External Liaison Officers) traveled to 
Vancouver to attend the National Conference of the 
Canadian Federation of Medical Students. The 
subject of post-graduate licensure and recent 
changes in the MCCQE examination formats were 
discussed. On October 16, Stephen Burnett (VP-
Executive) attended a conference at Dalhousie on 
Confidential Counseling and Support Systems in 
Medical Schools. Both student and administrative 
representatives from medical schools in Canada, the 
U. S., and Great Britain attended. The issues of 
confidentiality and availability of services to stu-
dents were discussed as important factors in an ef-
fective support system. The Council is also involved 
in the community through donations to various or-
ganizations and charities, including Med Outreach 
and the London Food Bank. 
The first in a series of "Brown Bag" lunches was 
held on October second. Dr. R. M. Barr, Assistant 
Dean of Postgraduate Medical Education spoke on 
the recent changes in post-graduate licensure and 
the implications of making earlier career choices. 
As always, many questions were generated and 
problems discussed. The Student Affairs and 
Learnil}g Skills Committee presents these sessions 
in an effort to address the concerns, interests, and 
questions of students on issues which will affect 
them now and in the future. Watch for posters dis-
playing upcoming speakers, including ethics 
seminars! 
By the time you read this, the Car Rally, 
Homecoming, and Oktoberfest will all have taken 
place. Future events sponsored by the Hippocratic 
Council include Tachycardia (Feb. 9-13) , a Food 
Drive , and the Meds Formal (early April - ALL 
YEARS AND CONSULTANTS INVITED!). Also be 
sure to watch for the health sciences variety night, 
"Tachycardia"- coming soon! 
Janice Barkey (Meds' 95) has been appointed by 
the Council to sit on the Medical Sciences 
Renovation and Planning Committee to keep stu-
dents updated on construction (to begin in Feb. 
1993) in the Medical Sciences Building. The changes 
planned will involve the Medical Students Lounge, 
Hippocratic Council and Meds Journal offices, 
CBLC (Computer Based Learning Center), and 
Learning Resources Centre. 
The members of the Hippocratic Council are 
your student representatives, and greatly value 
your suggestions and comments regarding 
Medicine at Western. If you would like to discuss 
any issues or events, or have any ideas, we en-
courage you to contact any member of the council : 
Mark Mensour, 
Ambrose Au, 
Stephen Burnett, 
Liisa Honey, 
Ingrid Tiessen, 
Merilee Brown, 
Elyse Lackie, 
Leslie Horton, 
Ambose Au, 
Mohammed Moussa, 
Natalie Nimetz, 
Jon Riddel, 
Katie Klein, 
Jeff Politsky, 
Ross Mantle, 
Shobhana Patel, 
Greg Hancock, 
David Fisman, 
Debbie Peneva, 
Britt Carlson, 
Jason Hodge, 
Janice Barkey, 
Dr. John Howard, 
(President, '94) 
(VP Academic, '95) 
(VP Executive, '94) 
(Social, '94) 
(Treasurer, '94} 
(Secretary, '95) 
(Past President, '93} 
(Ext. Liason Officer, '94) 
(Ext. Liason Officer, '95) 
(USC Rep., '95) 
(Comm. Relations Dir., '95) 
(Athletic Rep., '94) 
(Athletic Rep., '94) 
(Meds Journal Ed., '94} 
(Meds Associate Ed., '95} 
(Meds Associate Ed., '94) 
(Tachycardia Rep., '93} 
(Tachycardia Rep., '94) 
(Meds '94 Class President) 
(Meds '95 Class President) 
(Meds '96 Class President) 
(Renovation Rep.) 
(Honourary President) 
Q 
Mark Mensour and Stephen Burnett 
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CBLC & LRC UPDATE 
Renovations 
U nexpectedly, this past summer the Province announced it would provide $2.6 million in funding through "Jobs Ontario Capital" for 
renovations to the M139 area of the Medical 
Sciences Building. The renovated area will provide: 
three additional classrooms, eight small group 
teaching rooms, a larger Learning Resource Centre 
(LRC) and Computer Based Learning Centre 
(CBLC), office space for the Meds Journal and the 
Hippocratic Council, and a new medical student 
lounge and study room. The office of Instructional 
Resources will also relocate to the renovated area. 
The final design has not been completed but the 
anticipated start date for reconstruction of the area 
is January of 1993. Students will be notified of the 
exact date the area will be closed off and the 
locations of the temporary sites for the Student 
Lounge, Computer Based Learning Centre, and 
Learning Resource Centre. Janice Barkey (Meds' 95) 
is the student representative and liaison on the 
planning committee and the Hippocratic Council. 
Student input into the design of the area is 
welcomed. 
Nursing Student Access 
Another new change in the CBLC/LRC has been 
the addition of access to Nursing students. The 
Faculties of Nursing and Medicine are collaborating 
in the expansion of the LRC/CBLC and pooling 
their learning resources for mutual student use. A 
new staff person has been added by the Faculty of 
Nursing to assist in the Centre. Kathryn Morton 
joined the Learning Resource Centre in October of 
this year and is available to provide students and 
faculty with assistance in the Learning Resource 
Centre. 
Summer Student Projects 
Two instructional resources completed this sum-
mer by Leila Kasrai, Janice Barkey and Margherita 
Cadeddu are available for use in the LRC: 
(i) The Rectal Exam Module provides complete 
instruction on performing a rectal exam. Within the 
module the slide/tape program describes the 
procedure step by step and with the poster displays, 
shows examples of some of the more common 
lesions one may encounter during inspection. A 
male anatomical model of the pelvis and pathology 
specimens are also available. Finally, a prostate 
exam mannequin and manual provides an 
immediate opportunity for practising your skills. 
(ii) The Pelvic Exam Module is composed of a 
detailed instructional videotape demonstrating a 
Faculty News 
female pelvic exam, a female anatomical model of 
the pelvis, pathological specimens, and pelvic exam 
mannequins with a manual for practice. 
New Programs/Materials 
The following materials have recently been 
added to the collection: 
Computer Assisted Instruction: 
"AIDS: Vignettes for Physicians"; 
"Cardiovascular Physiology: Lab Experiments" 
(Macintosh/Videodisc); 
"Epidemic in a Small Town: Introduction to the 
Epidemiologic Process" (Macintosh/Videodisc); 
"Human Reproduction and Development"; 
"HyperHistology" (Macintosh/Videodisc); 
"The Impotent Patient" (Infowindow /Videodisc); 
"Right to Die? The Case of Dax Cowart" (Info-
window /Videodisc); 
Videotapes: 
"A.I.D.S.: Fears and Feelings"; 
"Breaking Bad News"; 
"The Gynecological Teaching Assistant: Pelvic and 
Breast Exam"; 
Mannequins: 
Breast Exam Simulators; 
Pelvic Exam Simulators with manual;; 
Prostate Exam Simulator with manual 
Slide/Tape Programs: 
"Clinical Methods: The Rectal Exam"; 
Reference Texts: 
"The Art and Science of Bedside Diagnosis"; 
"Atlas of Chest Infections"; 
"Atlas of Gastrointestinal and Hepatobiliary 
Infections"; 
"Atlas of Infections of the Skin"; 
"Atlas of Sexually Transmitted Diseases"; 
"The Ciba Collection of Medical Illustrations" 
Vols. 1-8; 
"Color Atlas of Allergy Series"; 
"A Guide to Physical Examination and History 
Taking"; 
"Infectious Diseases Text and Color Atlas"; 
"Microbiology Scope Publication Series"; 
"Principles and Practice of Infectious Diseases"; 
CD-ROM 
Scientific American Medicine "Consult". This is 
a subscription to a continuously updated com-
pendium of medical information which is indexed 
and searchable. The resource includes both graphics 
and text. We are very pleased to be able to offer CD-
ROM for the first time in the CBLC. 
Reference texts, slide/tape programs, and com-
puter assisted instruction on the DOS based system 
of terminals are accessible to Medical and ursing 
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students around the clock in the LRC. Videotapes 
and mannequins are currently only accessible when 
the CBLC is open. 
In Progress 
We are pursuing funding from the GradPact* 
and Foundation Western for a number of new 
materials as well as Medline in the CBLC. We feel 
that a Medline service would be an appropriate 
addition to the centre in the near future. [Editor's 
note : Third party funding is also being sought 
independently by Hippocratic Council, preferrably 
for a multidisk server, licensed for network access 
in the CBLC. The contact person on Council is 
Ambrose Au . According to Ambrose, Western 
Medicine is one of only two medical faculties in 
Canada without free Medline access for students.] 
------~------
CENTRAL PARK LODGES 
Access to electronic mail for students, a standard 
service for medical schools around the world who 
are connected via the interuniversity Vax network, 
is also on the drawing board. With this service, 
students could send and receive mail to universities 
around the world at low cost, with personalized 
billing through a system of access codes. The 
service also provides a large number of specialized 
bulletin boards for exchanging information. 
Q 
Beth Thorstenson, CBLC/LRC Director 
*The GradPact is a vehicle administered by 
Foundation Western through which students about 
to graduate may pledge money for the next three 
years to be used as the graduating class sees fit. 
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in the field of obesity, nutrition, psychology, and exercise physiology. It is 
a structured, multi-disciplinary approach to weight loss that addresses the 
whole patient with a food plan, a cognitive/behavioral support strategy, an 
exercise program, a maintenance plan and group support. 
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Doctor Information Centre 
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At Ortho, we're the experts in birth control 
and disease prevention. That's why we'd 
like to help make sure you learn oruy the 
things you want to learn. 
l!J Take care. Not chances. 
Feature Section 
TRIBUTE 
TO DEAN 
VALBERG 
In June of this year, 
Dr. Leslie Valberg 
stepped down as Dean 
of the Faculty of 
Medicine at The 
University of Western 
Ontario after a seven-
year term. 
Leslie Valberg was 
born in 1930 in 
Churchbridge, 
Saskatchewan. He 
entered the six-year 
medical program at 
Queen's University in 
Kingston at eighteen 
and graduated with a 
Gold Medal in 1954 . 
He completed res-
idency training and a 
Master's Degree in 
biochemistry by 1958. 
After a year in England 
as a Medical Research 
Council Fellow, he 
took a position at 
Queen's for 15 years as 
Lecturer. His research 
included studies on 
absorption and meta-
bolism of iron, zinc, 
and other heavy 
metals. He has become 
an authority on hered-
itary hemochromatosis. 
He served as Chief of 
Gastroenterology and 
Director of the Clinical 
u 12 
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Investigation Unit at 
Kingston General 
Hospital, and received 
Queens' Aesculapian 
Society (medical school 
student council) 
Lectureship Award for 
excellence in teaching 
in 1966. 
Dr. Valberg was 
Chairman of the 
Department of Med-
icine at The University 
of Western Ontario 
from 1975-85. In 1985, 
he was selected to be 
Western's new Dean of 
Medicine, a very high 
honour bestowed upon 
a physician. 
When Dr. Valberg 
entered the position, 
Western's 
undergraduate medical 
curriculum was 
organized roughly 
along the lines 
recommended by 
Abraham Flexner some 
seventy-five years 
before: two "in class" 
years followed by two 
"in hospital" years. 
Today, the "in class" 
segment has been 
extended by almost 
five months due to the 
introduction of 
Problem-Based 
Learning. 
Dr. Valberg has 
served the academic 
medical community in 
an eminent fashion for 
over thirty years, seven 
of those as our Dean. 
Through these efforts, 
his successor, Dr. 
McMurtry, has a strong 
legacy upon which to 
build his own vision of 
our medical school. 
We thank Dr. Valberg 
for leading us through 
the last even years. 
~ ONTARIO HOSPITAL ASSOCIATION 
~~~;CONVENTION & EXHIBITION J+ 0 Metro Toronto Convention Centre l l"': ' October 26, 27, & 28. 1992 ~~ "THE FUTURE IS NOW •.• Biueprints for Tomorrow's 
!C.; I:J Hospitals" 
Delegates attending the 1992 OHA Convention & Exhibition will 
h.ave many opportunities to participate in educa~ sessions 
planned in accordance with the overal theme '"The Future is Now: 
Blueprints for Tomorrow's Hospitals" and dealing with the key 
issues of Quality Management. Accountability, Employee/ 
Management Coopenotion and greate< Consumer Focus. 
More than 300 exhibitors are also planning to participate in the 
Convention, displaying for delegates the latest in hospital 
equipment and services. We hope you wiD take advantage of 
Canada' s largest and most comprehensive health care services, 
products and equipment exhibition and visit these outstanding 
displays. 
For registration i-'lformation please contxt the Ontario Hospital 
Associatlon (41 61429·2661 , Ext. 5600. 
CONTINUES TO SUPPORT HOSPITAL PHARMACY 
Corporate Office 
145 Jules-teger Street 
Bouchefville. Quebec, Canada 
J48 7KB 
I 5 I 4) 59 6-{)()()() 
Canada: 1-8()().361·3062 
Fax: (514) 59b-0003 
Mississauga/Ontario 
6600 Goreway Drive 
Mississauga, Ontario, Canada 
l4V IS6 
(416) 676-0006 
Canada: Hl()()-263· I 780 
Fax: (4 I 6) 670-0486 
I GI FOREMOST ~ERRIN -INPEPTIDES 
Ferring specializes in the researc h, 
development and di tribution of peptide 
medicines. In 1961, Ferring was one of the 
first pharmaceutical companies in the world 
to synthesize the pituitary hormone s, 
vasopres in and oxytocin, on an industrial 
scale. 
Ferring product are marketed worldwide. 
The company 's fir t peptide introduced to 
Canada wa DDA V J>@>, distributed under 
licence. In June 1989, DDAVP was approved 
for nocturnal enuresis and a new spray 
delivery form was introduced. 
Ferring Inc. was e tablished in 1986 and i 
the Canadian affiliate of Ferring B, 
Sweden. We are pleased that we now serve 
the Canadian market directly from our 
facilities in Willowdale. 
We can be contacted by calling .. . 
1-800-263-4057 
CONGRATULATIONS TO 
THE GRADUATING CLASS 
FROM ORGANON CANADA 
LTD./LTEE 
Organon Canada Ltd./Ltee 
565 Coronation Drive 
West Hill, Ontario 
MIE4S2 
Bus: (416) 284-6131 
Fax: (416) 284-6768 
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Me d 5 I 9 3 
by Les Wright 
G reetings all! Since fourth-year electives have tossed our class across the city, 
country, continent, and planet, 
there is little local Meds '93 news 
to report this time around. By 
the time this little missive is 
published, our mates will have 
returned from no doubt 
stimulating experiences in such 
places as England, Hawaii, Los 
Angeles, New York, 
Massachussetts, northern 
Quebec, Toronto, Kingston, and 
London, Ontario. Hopefully, all 
will make it home safely for class 
on November 30. 
Of course, the spectre of 
internship and its concomitant 
application process dogs senior-
year medical students no matter 
how much they try to hide. For 
those of you who have had early 
interviews, I hope they went 
well. For those of you awaiting 
responses, I wish you all the best. 
Incidentally, for anyone who still 
has not sorted it out, 
postgraduate education in 
Ontario as of June 1993 can be 
described as follows: there is no 
such thing as a "two-year 
internship" -there never was. 
One must pursue residency 
training of at least two years 
duration leading to certification 
either by the Canadian College of 
Family Physicians (in the case of 
Family Medicine training) or the 
Royal College of Physicians and 
Surgeons of Canada (in the case 
of specialty training) prior to 
being eligible for licensure. To 
this end, most Canadian faculties 
of medicine are offering Post-
graduate-Year-One positions in 
Family Medicine and Royal 
College specialties that may or 
may not resemble the rotating 
internships of old. Pursuing 
Family Medicine training as a 
"two-year internship" in order to 
be licensed prior to entering 
Royal College specialty training 
is being highly discouraged on 
economic and ethical grounds. 
An informal survey leads one to 
believe that many in our class 
have been so discouraged: most 
of us who are Royal College 
specialty-bound are going where 
the money is and applying di-
rectly to Surgery, Psychiatry, 
Internal Medicine, Paediatrics, or 
whatever. This is obviously quite 
a change in class sentiment 
compared to six months ago, and 
should hearten those who 
genuinely wish Family Medicine 
residency positions for the 
purpose of becoming primary-
care physicians. Hopefully, ev-
eryone will get what they want-
for now. 
A return to the lecture hall, 
after an eighteen-month-long 
hiatus, awaits us on ovember 
30, 1992. I understand that this 
first day includes a 
COMPULSORY orientation 
session that all MUST attend-
no skipping without a darn good 
reason. And, no, sticking around 
a Fiji beach for an extra day or 
two to study " photo-der-
matology" is NOT a good 
enough reason. See you all 
there! 
A look into the Meds '93 
crystal ball reveals some 
interesting goodies in store over 
the next few months. Among 
them: internship interviews, 
Tachycardia, more exotic 
electives, CIMS Match Day (a 
time of great joy or great sorrow, 
depending on your point of 
view), a little quiz over two days 
called the MCCQE Part 1 
(incorrectly referred to by many 
as simply "The LMCC"), and, if 
one is good, Graduation Day, a 
magical moment that will 
commemorate four (or five or 
seven) of the best years of our 
lives. Good luck to all, and I will 
keep you posted in these pages 
of more class developments as 
they unfold. 
Q 
Class Reports 
Me d 5 
by Justin Amann 
First of all, welcome back ev-erybody! We all made it back after our very varied 
summers. Some traveled, some 
worked, some did electives, some 
watched TV. (Sean), and some 
got married (Caroline, Jon, 
Naz ... congratulations! Any 
more volunteers- Nina?) 
Some rapid fire news: Burke 
is having a baby, or at least that's 
the scuttlebutt. (Personally, I 
think Judy deserves some credit 
too.) Last week he showed the 
class an ultrasound of the baby 
Baird at 14 weeks. It was giving 
Dad the finger. Burke will be 
only the second father in the 
class. (Brian is already a Dad to 
all of us.) 
Last week, two of our class-
mates reported a Kamyar sight-
ing. In fact, this has been hap-
pening with increasing fre-
quency, and renowned English 
UFO investigator Rory Tate pre-
dicts even greater frequency as 
clerkship begins. 
Jon Riddell claims he met 
Elvis over some beers at the Grad 
Club. He also claims our men's 
hockey team is going to win the 
championship this year. Only one 
of these claims is likely correct. 
How many of you pick Elvis? 
About a dozen of us wrote 
Part One of the American Board 
Exams back in September. A 
bargain at $200 to have your ego 
bashed in the city of your choice: 
Detroit, Ann Arbor, Boston or 
Montreal. Only Norm (my new 
hero) returned with tales of any-
thing but despair. 
Leila and Margherita orga-
nized a program this fall to edu-
cate high school students on the 
risks and benefits, hows and 
whys of sex. A bold move, taking 
frank talk about sex into high 
schools in London. Con-
gratulations to you two and to all 
who participated. 
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Steve Lai (Superguy) is re-
ported to have superhuman 
strength. This closet athlete is 
now a " beast at large" after 
slugging home runs in intramu-
ral baseball games and also has a 
contract offer to be the Dallas 
Cowboys' new QB (it's true!). 
Oktoberfest saw more reputa-
tions fall this year. 
The Meds soccer team, Team 
Dartos, finished the season 5-0, 
and is aiming for a second 
straight championship. Good 
luck in the playoffs. 
During the Blue Jays' run for 
the World Series, study time took 
as big a beating as Atlanta and 
Oakland combined. UMEC, in a 
shining display of magnanimity, 
has agreed to lower the pass re-
quirement for the upcoming ICC 
exam by 2% per playoff game 
watched, plus an extra 5% for 
anybody who drove to Toronto 
for game 5. Dr. Haase has been 
usurped by Roberto Alomar as 
honourary class presi-
dent.Finally, clerkship is almost 
upon us. Psych yourselves up, 
it' s like a real job. You gotta be 
there everyday! Use all the re-
sources at your disposal. And 
remember: it's more than a job, 
it's slave labour. So enjoy it! 
Me d s I 9 5 
by James McNabb 
Welcome back, kids. I can't tell you how thrilled I was to see 
everyone arrive back to school 
with smiling faces and refreshed 
minds in anticipation of what is 
sure to be a most exhilarating 
and inspirational experience in 
2nd year Medicine. I'm relatively 
new to this article-writing thing, 
but, in my time away from a 
hectic academic schedule and 
volunteer work down at the 
mission, I have attempted to as-
semble a brief account of the re-
cent events of this young school 
year. Please note at this time that 
this article is being written from 
the standpoint of one medical 
student and does not necessarily 
represent the opinions held or 
the events being partaken in by 
the entire Meds '95 class. 
That said, I would like to ex-
tend heartfelt congratulations on 
behalf of the entire class to Jeff 
Spence and Nicole Desmarais. 
Nicole wed this past summer 
and Jeff recently witnessed the 
birth of his firstborn son. Best 
wishes also to Martin McFarlane 
and Donika, and to Ambrose Au 
and Lydia who have announced 
their engagements to be married. 
Congratulations folks! [Editor's 
note: Felicitations to the author 
and Ms. Andrea "But-we're-not-
living-together" Brkovich are 
also in order, it's their ten month 
anniversary. Knock yourselves 
out.] 
Turning now to events in 
which i t might be considered 
ethically and morally correct for 
the whole class to participate, the 
first off was Disorientation 
Week. Apparently all went well 
as our volunteer staff assisted 
the first years in getting accus-
tomed to their new surround-
ings. Al though they tried, the 
Meds '95 crew didn't quite seem 
to have the ingenuity required to 
surpass the former year's artistic 
prowess in 0-week T-shirts. But 
alas, who can be expected to top 
such a culinary coup in fashion? 
Thanks once again, Meds 
'94 ... with bacon. 
The Fanshawe Picnic was 
next. An annual get together 
that generally provides enter-
tainment of mammoth propor-
tions. There were, however, some 
changes to the picnic this year, 
briefly: the 1st year class cheated 
their way to victory in the boat 
races against the 2nd year class 
instead of the traditional vice 
versa, D. J. music was provided 
instead of Rockin' Ramsay and 
his All Girl Orchestra, and 
professional bartenders were 
hired in order to minimize 
financial loss from handing out 
free beer to free-loading 2nd 
years. If only the two hired bar 
girls had attended those classes 
at bartending school where they 
would have been taught that 
kegs, unlike fine wine, need not 
be tapped prior to consumption 
in order to breathe ... 
Fanshawe was soon followed 
by war games. Although present 
in smaller numbers this y ear 
(thus forcing our medical heroes 
into battle against a squad of 
gun-happy weekend warriors 
from the Police Force instead of 
against one another) our platoon 
was able to prove victorious. The 
win can be attributed to many 
brave souls, not the least of 
which was an overly bunker-ag-
gressive 3rd year (physician, heal 
thyself), as well as the leadership 
strategy and courage above and 
beyond the call of duty exhibited 
by our fearless, armed forces 
trained, Thomas "Magnum" 
Hurley. Conspicuous in their 
absence were the female 
brigades, led by Jen Green. al-
though they were sorely missed, 
we did understand when we 
were informed they had been 
hired by a secret government 
task force in combination with 
the CIA and the Green Berets. 
Our thoughts are with y ou, 
ladies - bring home those 
P.O.W.s. 
The last event which must be 
recounted is Oktoberfest. Two 
Murphy's Line school buses 
were responsible for transport-
ing our thirsty folk to the 
Concordia Club in Kitchener. 
Thankfully, sing-songs were cut 
short with 47 bottles of beer re-
maining on the wall and, hey, the 
bus driver had sped up a little 
bit. As the evening wore on, no 
one was sure whether this was 
merely an opportunity for some 
guys and gals to get together for 
a few drinks, or a fo rced 
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impromptu version of "The 
Young and the Restless" by Das 
Fuhrer for a few of the med 
school couples. Most had a great 
time regardless - who needs to 
have sex for the next month 
anyway? Oh, by the way, Brian 
Bell was successful in defending 
his Murphy Bus Lines Wrestling 
title, and, in his kind hearted 
manner, has decided to donate 
his winnings to the Oktoberfest 
Illegitimate Child Fund as well 
as to Sketchely Cleaners for 
Hart's jacket. 
Well, I've just looked at the 
time, and appear to be woefully 
behind in my 3rd revision study 
schedule. Good luck to one and 
all during exams, and we hope to 
see you all at those well de-
served post-exam celebrations. 
Me d s .I 9 6 
by Jay Nathanson 
So this is medical school. For an overwhelming majority of us, the year began (and 
for some of us, remains) as a 
non-stop celebration of the 
detoxifying marvels of the 
human liver. After a host of 
orientation activities, including a 
class barbecue, a party at the 
Graduate Club, a pub at the 
Rideout, a sports day in Gibbons 
Park, a beach day in Grand Bend, 
and a picnic in Fanshawe Park, 
we were getting acquainted with 
each other. Special thanks to the 
class of '95, and especially Britt 
and Jeff, for making orientation 
such a success. 
With the commencement of 
classes, the revelry and merri-
ment continued unabated. Our 
class was now starting to feel 
very comfortable together, and 
we met for a Star Trek season 
premiere party and movie 
nights. By the time that the 
Health Sciences Pub rolled 
around, it was hard for us to be-
lieve that we had known each 
other for such a short time. 
Within weeks, however, we 
had moved on to more cerebral 
pursuits, and were faced with 
several serious medical dilem-
mas: Welsh-Allyn or Heine? 
Littman or Tycos? Every 
October, the instrument compa-
nies, smelling the new and not 
quite yet debt-ridden medical 
students, visit Western to eluci-
date on their products' distinc-
tive features and inform us 
where the other brand is lacking. 
We could look forward to 
spending over six hundred dol-
lars on various "toys" that, for 
the most part, will rarely be used 
and, when needed, can be found 
in abundance in any hospital. 
The first few weeks of classes 
also brought with it a very im-
portant lesson: if you're in 
medicine for the money, start 
writing textbooks. 
Then we started dissections. 
Six medical students, dressed in 
(initially) white lab coats, trying 
to ignore the smell, exploring the 
wonders of human anatomy, 
hunched over a cadaver, en-
grossed in the task of finding one 
nerve, vessel, or node among 
thousands. The ultimate in bond-
ing. 
Finally, class elections were 
held. Jason, who had been on the 
campaign trail since the very 
first day (if not before), was 
elected Class President. As well, 
Farhan was chosen to be our 
Vice-President and April was 
elected as Treasurer. 
Well, that's the way it is. I 
hope everyone has a great first 
trimester (or had a great 
trimester - depending on how 
long it takes for the Journal to 
come out), and I'll see you next 
Journal. 
Cla s s Reports 
The U.W.O. Medical Journal is an inter-disciplinary medical 
science publication. The 
Journal was established in 
1930. Since that time the 
Journal has always published 
original articles of topical or 
historic relevance. 
The continual main-
tenance and improvement of 
a high standard of literary 
excellence in the U.W.O. 
Medical Journal requires a 
great deal of commitment on 
the part of the Journal staff. 
Clearly, however, effort alone 
is not enough! Rising 
operating costs make the 
accumulation of external 
funds an essential factor for 
the successful operation of 
the Journal. 
One important method to 
obtain additional financial 
resources is through 
donations. The Journal 
encourages all post-graduate 
readers (including alumni) to 
make a commitment to the 
U.W.O. Medical Journal in 
the form of a cash donation. 
These contributions may be 
$20, $40, $60, or more. Sums 
of $40 or more result in the 
designation of the donator as 
a patron of the U.W.O. 
Medical Journal. 
Thank you kindly for 
your continued support. 
The U.W.O. Medical Joumal 
N.B. Donations are tax 
deductible; receipts will be 
forwarded. 
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The Only Advantage 
You Need 
The Medi-Dent Advantage Card sets you apart 
as a member of an elite group. Medi-Dent 
Advantage Card members have access to a 
pre-approved line of credit for the purchase of 
equipment, furnishings, leaseholds etc. in a quick, 
simple and easy to use process. Contact your 
Medi-Dent representative for full details 
Mecli-Dent 
A division o{Commcorp Finandal s~rvias Inc. 
Personalized Lease Financing 
And Financial Services 
We're working for you. 
We represent Parke-DiMS ... a You also may be happt to know 
compartf of more than 600 people that there's something exciting going 
ded icated to your health and on 1n our laboratories right now that 
well-being. we expect to be our greatest 
We are the people who contribution to your healthcare so 
deYeloped and produce medications far. You'll be hearing about it very, 
that help to control epilepsy. We are very soon. 
the ones who make cardiovascular Here's to a healthier Canada. 
agents that help to grve people wrth Here's to a healthier you. 
heart disease a more !JOOlising future. 
We Mn make products that help you PAJIKE·IJAIRS 
rest more comfortably when you _.._ ... ..., 
comedc>Nnwrthacold. ~0::.:...~~::':::.. E:J 
Feature 
Section 
This month's Feature Section is 
Substance Abuse & Toxicology. 
Articles range from the obcure to the 
more general. 
On page 17 is Dr. David Smith's 
discussion of co-presentation of chemical 
dependency & mental illness. Aron Ross 
writes about the obscure practice of 
toad licking (p. 31). Anne Silas and 
Dr. R. Gerace present the effects of 
cocaine toxicity (p. 39). Plus 
a drug research update 
and more! 
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DEPENDENCY CHEMICAL 
MENTAL 
AND 
ILLNESS: 
A PSYCHIATRIC CHALLENGE 
I TRODUCTION 
I n the study of chemical dependency, the term "comorbidity" refers to the simultaneous occurrence of psychiatric disorders and alcohol 
or drug abuse disorders. Affected persons are 
commonly referred to as "dual-diagnosis" or "dual 
disorder" patients. The "Vision for the 90's" 
submitted to the Ontario Government highlighted 
the need for improved assessment and treatment of 
the dual-diagnosis patient. Estimates place the 
number of dual-diagnosis patients in the province 
at 250,0009 • Review studies show that 40 percent or 
more of psychiatric inpatients have a chemical 
dependency diagnosis as well as a psychiatric 
diagnosis9•10 • A recent study at the orth Bay 
Psychiatric Hospital revealed that 56.7 percent of 
psychiatric inpatients satisfied the criteria for 
chemical dependen cy according the MAST 
[Michigan Alcohol Screening Test]. In spite of the 
frequency of drug abuse and drug addiction among 
the psychiatric patient population, most psychiatric 
units in general hospitals and admitting units in 
provincial hospitals d o not routinely assess for 
chemical dependency, or provide structured 
intervention. 
CASE VIGNETTE 
Don B. is a 30-year-old male alcoholic. He 
reports that he was a slow learner in school and was 
labelled as a hyperactive child. He began abusing 
alcohol as a teenager and reports that he drank to 
"feel normal". From the age of 18 to 28 Don entered 
detoxification centres more than fifty times. He 
completed six alcohol treatment programs. Don was 
never able to remain sober for longer than six 
months in spite of his AA (Alcoholics Anonymous) 
ABOUT THE AUTHOR: 
Dr. David W. Smith completed his medical education and psychiatric 
residency at the University of Gllifomia at Los Angeles. He is board certified 
in psychiatry by the American Boord of Psychiatry. Dr. Smith has held a 
number of academic positions, which include: Medical Director of tile St. 
Thom12s Psychiatric Hospital's Addiction Rehabilitation Unit, Assistant 
Clinical Professor of Psychiatry at the University of Western Ontario, a 
member of the Dual Disorder Committee of the American Society of 
Addiction Medicine, and faculty member of The Sdwol for Addiction Studies 
of the Addiction Research Foundation . 
David W. Smith, M.D. 
attendance where he obtained a sponsor and 
worked on the 12 steps towards recovery. Don 
reported that he experienced rapid mood swings 
when sober. He reported "My mood would go from 
the floor to the clouds in a rna tter of hours." 
Assessment at the St. Thomas Psychiatric Hospital 
Addiction Unit, determined that he might be 
suffering from an atypical affective disorder and he 
was s tarted on Lithium Carbonate. Li thium 
treatment has allowed Don to enjoy long-term 
sobriety for the first time. After two weeks of 
Lithium therapy he reported,"For the first time in 
my life I feel like an earth person." 
Don B's story illustrates the tragedy of delayed 
diagnosis. Chemical dependency practitioners and 
psychiatrists must examine individuals who 
frequently relapse more closely in order to 
determine possible psychiatric disorders. 
IM P EDIMENTS TO PRO PER A D DICTI O N 
ASSESSMENT 
Historically, drug addiction was not felt to be a 
distinct disorder. Until 1968, diagnostic nosologies 
did not allow for a separate addiction diagnosis 
classifying alcohol addiction and drug addiction as 
subtypes of sociopathic personality disorders7 • In 
spite of diagnostic clarification of addictive 
disorders in the DSM-111-R, practitioners continued 
to believe that treatment of a patient's mental 
disorder would automatically cure the chemical 
dependency. The professional community now 
realizes that each disorder requires treatment. 
Chemical dependency education was not a part 
of the curriculum of many medical schools until 
quite recently. University psychiatric departments 
have typically involved themselves in chemical 
dependency research. Psychoanalytic thinking 
continues to interfere with the understanding of the 
disease of chemical dependency. In add ition to 
being better trained in assessment techniques, 
physicians need to become aware of the importance 
of the self- help community. AA, A[narcotics 
anonymous] Alanon and Adult Children of 
Alcoholics groups are critical to recovery. 
Diagnosis of a psychiatric disorder based solely 
upon the presenting symptomatologt2 occurs too 
often in the mental health field. Physicians 
commonly review the outside psychiatric records of 
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patients admitted to an addiction unit and to note 
numerous psychiatric symptoms which lack 
documentation of the temporal relationship 
between the symptoms and drug or alcohol use. 
Alcohol and drug histories are absent from many 
files . Patients are diagnosed incorrectly and given 
antidepressant medication or antipsychotic 
medication unnecessarily. 
IMPEDIMENTS TO PROPER MENTAL HEALTH 
ASSESSMENT 
In addition to impediments in the assessment of 
addiction, negative attitudes and lack of 
information have prevented addiction professionals 
from making adequate mental health assessments. 
Addiction treatment professionals are frequently in 
recovery themselves, and tend to promote the form 
of treatment that was helpful for them. This usually 
involves a strong 12-step AA/ A app r oach. 
Although a strict 12-step approach is critical with 
some patients, the dual-disorder patient has caused 
the addiction treatment community to become more 
flexible in its approach. For example, the addiction 
field has had to re-examine its commonly-held 
belief that all drugs are bad drugs. AA has clearly 
stated its position in a 1984 publication entitled 
"The AA Member-Medication and other 
Drugs"[Alcoholics Anonymous 1984; 9 ]. The 
pamphlet states;"lt becomes clear that just as it is 
wrong to enable or support any alcoholic to become 
re-addicted to any drug, it's equally wrong to 
deprive any alcoholic of medication which can 
alleviate or control other disabling physical and/ or 
emotional problems." 13• 
Addiction professionals must understand that a 
relapse to chemical dependency may not be the 
result of the patient's failure to "Work the 
program." In the case of the dual disorder patient, a 
relapse to chemical dependency could result from a 
relapse of the patient's mental illness. Failure to 
attend self help groups should not always be seen 
as a resistance to recovery from chemical 
dependency. For example, many months may be 
needed for a patient with a generalized anxiety 
disorder with panic to feel comfortable in a group 
setting. Given the heterogeneity of the dual-
disorder population, individualized treatment 
planning is essentia14 • Traditionally, individualized 
treatment planning was frowned upon and was 
seen as evidence of the patient attempting to 
manipulate the addiction treatment system. There 
are still treatment programs where indiv idual 
sessions are discouraged. Patients suffering from 
Post-trauma tic Stress Disorder from incest, or 
patients with panic disorder, are unlikely to talk 
about their experiences in a group until they are at 
ease individually. The dual-disorder patient 
generally does poorly in a treatment setting that , 
places the same expectations upon on all patients. ~ 
PRACTICAL APPROACHES TO ASSESSMENT 
Before making a psychiatric diagnosis on a 
patient with a chemical dependency an 
understanding of the following principles: the 
acute, chronic and withdrawal effects of the 
patient 's drug or drugs of choice; common 
symptoms of protracted withdrawal, and the stage 
of recovery that the patient is in . Most studies 
suggest that drug abuse does not cause major 
mental illness [excluding drug induced mental 
disorders], but either exacerbates it or hastens its 
onset11 • 
An accurate psychiatric diagnosis cannot be 
made while the patient is under the influence of 
alcohol or tests positive for illicit drugs in the urine 
or blood . Serious consideration of a psychiatric 
diagnosis should not be undertaken for at least two 
to four weeks after detoxification. If the psychiatric 
symptoms worsen in spite of abstinence, it would 
be more likely that an underlying psychiatric illness 
is present. 
Gorski has described the recovery process from 
chemical dependency in stages6• The pretreatment 
phase is characterized by the patient denial of the 
presence of addiction. Unless there is a documented 
period of abstinence during which psychiatric 
symptoms were present, a psychiatric diagnosis 
during this period is inappropriate. Detoxification 
or stabilization is marked by psychiatric and 
physical symptoms induced by drug or alcohol 
withdrawa18 • Withdrawal from alcohol, stimulants, 
sedative/hypnotics, marijuana or opiates produce 
unique mental status changes that mimic major 
mental illness. 
Alcohol withdrawal can cause agitation, visual 
hallucinations and severe depression. The agitation 
and hallucinations should cease by the end of the 
first week of abstinence; depression, however, can 
persist for weeks. If the depression worsens beyond 
the two to four week period, treatment of the 
patient with antidepressant medication may be 
necessary. 
Stimulant withdrawal, [i.e., cocaine and 1 
amphetamines] produces depression, lethargy, 
insomnia and occasionally a paranoid psychosis. 
The paranoia induced by cocaine rarely lasts longer 
than forty-eight hours, whereas it may last for 
several weeks in the case of amphetamines. Urine 
screening is beneficial in clarifying the etiology of a 
paranoid psychosis. 
Sedative/hypnotic withdrawal produces 
agitation, irritability, insomnia, emotional lability 
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and depression . The syndrome of protracted 
abstinence is particularly evident in 
sedative/hypnotic withdrawal 14 • Protracted 
abstinence is a central nervous system abnormality 
characterized by neural hyperexcitability, altered 
thyroid function, poor visual spatial perception and 
central neurochemical receptor alterations. 
Protracted abstinence can last for weeks to months 
after the acute withdrawal has ceased. Clinically, 
protracted withdrawal is evidenced by insomnia, 
anxiety, depression, memory disturbances and 
irritability. Although this syndrome has been 
associated with all addictive substances, it seems to 
be most pronounced with alcohol and 
sedative/hypnotics. Symptoms of protracted 
withdrawal are frequently episodic whereas the 
symptoms of an emerging mental illness are 
consistent and persistent. 
Opiate withdrawal produces agitation, 
restlessness, insomnia, depression and emotional 
lability. Withdrawal from cannabis can produce a 
similar syndrome however the symptoms are less 
pronounced. Unique to marijuana is the prolonged 
time that it is stored in body fat. In chronic 
cannabis smokers the withdrawal period could last 
for four to six weeks15• 
The next stages of recovery are early, middle, 
and late. Early recovery is marked by a strong focus 
on relapse prevention and adapting to a sober 
lifestyle. Depressions are common during this 
period as patients take inventory of the effects that 
addictive chemicals have had on their lives. These 
depressions, however, are frequently situational. 
Middle recovery is characterized by the 
development of a balanced lifestyle. Late recovery 
is characterized by development of healthy self 
esteem, personal growth and healthy living. 
TREATMENT ISSUES 
The most common psychiatric diagnoses 
coexisting with a diagnosis of addiction are 
schizophrenia, affective disorders, post-traumatic 
stress disorder, generalized anxiety disorder and 
antisocial personality disorder. These disorders 
cannot be successfully treated if the patient is using 
mind- altering chemicals. 
SCHIZOPHRENIA 
In my experience of working with patients with 
schizophrenia, two unique issues emerge. Patients 
with schizophrenia enjoy the positive atmosphere 
recovering in the community. There is an 
expectation of recovery that does not exist in most 
mental health settings. This sometimes causes 
patients to want to shed the mental illness label 
Feature Section 
and stop their antipsychotic medication. Patients 
must then be educated about their illness. 
Additionally, with respect to sobriety and recovery, 
patients become more aware of uncomfortable side-
effects from antipsychotic medication. Clinicians 
should be sensitive to this problem and be willing 
to make reasonable adjustments in dosage. 
AFFECTIVE DISORDERS 
A common problem encountered in this group 
of patients is trying to convince them that 
medications for affective disorders (antidepressants 
or Lithium Carbonate) do not produce physical 
dependence. Twenty-five percent of alcoholics 
suffer from major affective disorders8 • Studies 
reveal that comorbid depression predicts poor 
vocational functioning, more substance use, and 
greater dysfunction. 
GENERALIZED ANXIETY DISORDER 
Ten to twenty percent of alcoholics suffer from a 
generalized anxiety disorders. Typical patients with 
alcohol dependence and generalized anxiety 
disorder develop alcoholism as a byproduct of their 
attempt to ease anxiety. Practitioners must be aware 
of the extreme physical discomfort these 
individuals' experience during recovery. 
Pharmacological treatments, along with behavioral 
interventions, are thought to be the most effective. 
As stated previously, these individuals will require 
a lot of time before they will participate in group 
discussions. Patients with generalized anxiety 
disorder may do best in individual addiction 
intervention and treatment. 
POST-TRAUMATIC STRESS DISORDER 
Symptoms of Post-traumatic stress disorder 
frequently appear spontaneously as recovery 
progresses. Most addiction specialists suggest 
waiting for several months before engaging the 
patient in "uncovering psychotherapy." The 
patient with Post-traumatic stress Disorder is an 
exception. If the patient is experiencing flashbacks 
of the incest perpetrator, nightmares, severe 
emotional lability, depression, and anxiety, to a 
degree that causes them to be dysfunctional, then 
therapy should not be postponed. Depending upon 
their symptomatology, patients may require 
antidepressants and psychotherapy. Recovery 
support groups can be most helpful with these 
individuals. If the patient is female, she may not 
feel comfortable in mixed AA/NA groups and 
may prefer to attend Women For Sobriety 
meetings. 
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ANTISOCIAL PERSONALITY DISORDER 
A patient who presents for addiction treatment 
with a diagnosis of Antisocial Personality Disorder 
should be carefully reviewed for accuracy of 
diagnosis . .Knowing whether the antisocial disorder 
predated the chemical dependency or occurred as a 
result of it is important. Antisocial Personality 
Disorder has been found to be present in four 
percent of males and less than one percent of 
females in the general population. Among alcohol 
abusers, however, the incidence increases to fifteen 
percent of males and ten percent of females?. 
Longitudinally, the diagnosis has been shown to be 
unreliable. MMPI [Minnesota Multiphasic 
Personality Inventory] abnormalities frequently 
return to normal in this patient population after 
long-term sobriety. The therapist must be careful 
not to allow his or her anger with the patient to 
prompt a non-therapeutic decision to be made. 
Many patients demonstrating Antisocial Personality 
have been victims of severe child abuse resulting in 
them having frequent conflicts with authority 
figures. Clear therapeutic contracts with these 
patients which contain the therapist's expectations 
regarding attendance at counselling sessions, self 
help groups and drug testing is critical. In instances 
where there is unresolved anger, depression or 
trauma concerning childhood issues, indi idual 
psychotherapy may be indicated. 
SUMMARY 
Patients with a dual-disorder of chemical 
dependency and major mental illness represent a 
challenge to the treatment philo ophies of the fields 
of mental health and addiction. An understanding 
of each area is essentia14• Without the development 
of an integrated approach to the treatment of this 
patient population, unnecessary delays in diagnosis 
and treatment will continue to occur, resulting in 
unnecessary suffering. 
P11 
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CALIFORNIA SUBSTANCE 
PROGRAM 
ABUSE 
Dennis Zander, Meds'94 & Ross Mantle, Meds '95 
The five day "Professional in Residence Experiential Program" offered at the world famous Betty Ford Center in Palm Springs 
California was the beginning of a new approach to 
substance abuse for both of us this summer. The 
centre was founded in 1982 by Mrs. Ford, former 
First Lady of the United States. She was also a 
former alcoholic and drug addict. Based on her 
experiences in a US Navy treatment program, Mrs. 
Ford was inspired to create a new way of treating 
civilian substance abusers outside of the hospital. 
Since 1982, 14,000 individuals have graduated from 
the program and the Center has become recognized 
worldwide. The trendy Palm Springs location and 
$11,000 (US) price tag for a one month stay have 
made this desert enclave the subject of much 
National Enquirer lore, since Elizabeth Taylor and 
other well known Hollywood figures have been 
admitted over the years. In fact, the cost of 
treatment at the Center is in the lower half of the 
price range available for similar programs across 
the United States. Further, less than 1% of clients are 
celebrities. In addition, $250,000 (US) in financial 
aid is available each year to those in need. 
"Betty Ford" 
DRUGSTORE 
OFFERING 
FREE DELIVERY 
SERVICE ON ANYTHING WE SELL 
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For the alcoholic or addict, both inpatient and 
outpatient options are available. A comprehensive 
aftercare program following admission and a family 
program which takes place during the patient's stay 
are standard and included in the fee . The Center 
strongly encourages the families of subs tance 
abusers to become involved in family rehabilitation 
to decrease the likelihood of relapse upon return of 
the abuser to the home environment. 
The four week inpatient program is highly 
structured with therapeutic activities planned from 
6 AM to 10 PM every day. The patients' schedules 
include group therapy, art therapy, chores, exer-
cises, lectures, Alcoholics Anonymous (AA) 
meetings, meditation, and some time for socializing. 
The inpatient centre consists of three single sex 
units and one mixed unit with twenty beds in each. 
As part of an attempt to keep patients focused on 
treatment, diversions such as novels, musical in-
struments, electronic devices, clothes, telephone 
conversations, or other diversions are either not 
allowed or kept to a bare minimum. Also, re idents 
are not allowed to socialize with patients in other 
units. Dress and conduct codes are conservative and 
enforced with threat of dismissal. Despi te the 
restrictions on individual freedoms and activities 
within the Center, the doors are not locked and any 
patient may leave at any time and receive a partial 
refund. evertheless, the large number of rules 
create a certain "us and them" sentiment among the 
patients which contributes to their camaraderie and 
is a constant source of sardonic humour. ew 
patients are continuously introduced to the unit as 
graduates are discharged. ewcomers are therefore 
able to witness other patients in their unit at all 
stages of recovery and can gain inspiration from 
those preparing to go home. Importantly, the enior 
"inmates", as they sometimes call themselve , also 
gain sell esteem from helping newer patients adjust 
to the "system." 
The outpatient program is identical to the 
inpatient program except that patients return home 
in the evenings instead of staying in the unit. As 
well, the cost is less. The cost of both the inpatient 
and outpatient programs include flight arrange-
ments and hotel accommodation for one family 
member in the week-long family treatment pro-
gram. Additional family members are encouraged 
to attend, but must pay for their own expens s. The 
family program attempts to provide close relatives 
insight and therapy into their family member 's (and 
perhaps their own) addiction . Since patients' 
families are usually dysfunctional, either resulting 
in or from the patient's addiction, the Center 
encourages extersive aftercare. 
A unique feature of the Center is the 
"Professional in Residence" program. The program 
is an opportunity to learn about the Center and to 
actually participate in treatment for 5 days. The 
Center provides a travel stipend and free 
accommodation through donations and grants 
designed to promote "Aunt Betty's" treatment 
philosophy. Police officers, doctors, college athletics 
coaches, teachers, as well as medical students (the 
largest contingent) participate. Admission to the 
medical student program is fairly competitive; less 
than one in eight applicants are accepted . This 
summer, four groups of sixteen medical students 
were invited. In each session, eight students partici-
pated in the inpatient program while the other eight 
were involved with the family program. Schools 
from all over the United States and Canada were 
represented. 
Our days began at 6 am with a short bus ride 
from the Howard Johnson's Hotel where all the 
medical students stayed free of charge. Although 
we were exceedingly well-briefed beforehand, no 
one was spared the anxiety of stepping into an un-
familiar family group or onto units inhabited by 
twenty strangers 
with evere ad-
diction problems. 
Would we be ac-
cepted or perceived 
as intruders? I 
recall watching the 
emotions on the 
face of the first 
woman I met 
change from 
surprise to em-
barrassment as she 
shuffled along the 
hall still "coming 
down", her hair di-
she-veled, and her 
mo v ements 
unsteady. Oddly, 
by the end of the 
afternoon this lady 
and I were be-
coming friends. 
She had a quick wit 
and a warm smile. 
She also had a long 
series of purple 
marks on the 
medial surfaces of 
her forearms where 
she had injected 
heroin. Most of us 
in the program 
quickly realized 
that this was not 
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the time to play junior doctor. We were there to 
learn from them, not the reverse, and they knew it. 
A typical day began with a thirty minute 
meditation walk around the Center and breakfast 
w ith the patients . Morning activities involved 
exercise (everyone participates, no exceptions), 
lectures, and group therapy. Departure to each 
activity was preceded by a call to "circle". In circle 
we recited the Serenity Prayer ("God grant me the 
serenity to accept the things I cannot change .. . "), 
joined hands and chanted the unit chant (" orth 
Hall, we stand tall, no more drugs or alcohol.. .") . 
Three lectures each day were designed to provide 
the patients with insight into their addiction and 
ranged from the pharmacology of abuse, to spiri-
tuality, to family dynamics and self-esteem. The 
lectures were of a consistently high calibre and were 
often extremely inspirational and entertaining. In 
addition to these activi ties medical students at-
tended lectures on the behind-the-scenes workings 
of the Center. 
Group therapy can be intensely emotional and 
personal-this was definitely one of the highlights 
of the program for us. While patients occasionally 
greeted our presence in "group" with mistrust, most 
of us were quick ly accepted and actually 
encouraged to participate. 
Activities related to the AA Twelve-Step 
program, upon which treatment at Betty Ford is 
based, are carried out in the afternoons. The first 
five steps take p lace at the Center and the 
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remainder are executed after discharge. Aocoholics 
Anonymolus meetings, which may also include 
graduates from the centre and members of the 
community, are held on the campus in the 
evenings. 
For the medical students, there were more 
memorable times waiting each night around the 
hotel hot tub as we sat and soaked, reflecting on 
the day. Comparing notes, we found that without 
exception, every student experienced a bond to the 
patients they were in contact with. We also realized 
the unfortunately high relapse rate after a single 
course of treatment. According to veteran 
therapists at the Center, there is no way to predict 
an individual's long-term sobriety. 
The Betty Ford Center staff, approximately 
eighty-percent of whom are recovering themselves, 
put on an unforgettable training program for us. 
We feel that the experience was extremely valuable 
to us. The interpersonal skills we refined will assist 
us in all areas of medicine. 
Addicted and alcoholic persons have a message, 
and perhaps a lesson, for those willing to listen. 
Q 
Applications to attend the Betty Ford summer 
training course may be obtained by writing to : 
Betty Ford Centre, 
Training Department, 
3900 Bob Hope Drive 
Mairape, Ca 922702 
Car!Pg 
For 
Canada~s 
Health. 
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THE POTENTIAL VALUE OF 
PSYCHEDELIC DRUGS: 
THE MPTP AND MDMA STORIES 
INTRODUCTION 
H allucinogenic agents have a long history of being prepared to create altered sta tes of mind. This history may even predate 
ethnologic records of these agents (see article by 
Aron Ross in this issue). Ethnologically, 
hallucinogens have been prepared from n a tural 
sources and used for ceremonia1, religious, and 
medicinal purposes. A recent trend in the use of 
mind-altering substances 
involves chemical synthesis 
of psychedelic drugs for 
recreational use-the so-
called "designer drugs." In 
addition to their recreational 
use, psychedelic drugs are 
also used therapeutically 
and investigationally. The 
synthesis of psychedelic 
agents is based on 
legitimate pharmaceutical research, and has 
resulted in the production of a variety of mind 
altering substances, each with an interesting history. 
The two major classes of designer drugs are 
synthetic phenylethylamines (mescaline analogs) 
and synthetic opioid derivatives. This paper 
presents a discussion of two psychedelic drugs: 1-
meth y 1-4-phen y 1-1,2,5,6-tetrah ydropyr idine 
(MPTP}, a derivative of meperidine synthesis, and 
-meth y 1-3 ,4-meth y lene-dioxyam phetamine 
(MDMA), a mescaline analog. MPTP is used in the 
development of animal models designed to further 
understand the pathologic basis of Parkinson' s 
Disease. MDMA has potential therapeutic value in 
the treatment of patients who exhibit psychological 
disturbances. 
MPTP (1 - METHYL-4-PHENYL-1,2,5,6-TETRA-
HYDRO PYRIDINE) 
MPTP, a known neurotoxin, was discovered as a 
result of a bizarre detective story. In the late 1970's, 
a 23-year-old chemistry graduate student in 
Berkeley, California spontaneously developed 
severe Parkinsonian-like signs and symptoms that 
lasted 18 months . Autopsy revealed selective 
degeneration of the substantia nigra, thus 
supporting the diagnosis of Parkinsonisml. Further 
Jeffrey Poltisky, Meds '94. 
research by scientists from the National Institute of 
Mental Health (Bethesda, Maryland) showed that 
the subject was a drug addict and had been 
synthesizing meperidine analogs for illicit sale. 
Analysis of chemical samples obtained from the 
student's basement laboratory revealed MPTP as a 
contaminant. Subsequent to this event of sudden 
death, investigators identified several young adults 
in northern California who presented with virtually 
identical clinical signs 2•3 • The facts that these 
individuals were also d rug 
addicts and that the second 
outbreak also occurred in 
northern California Led 
investigators to suspec t a 
toxic contaminant. Indeed, 
drug samples analyzed from 
an illegal lab ora tory showed 
MPTP to be the likely 
toxin2•3 • These clinical 
observations prompted 
pharmacologists and clinicians to probe the 
physiologic, pharmacological, and toxicological 
aspects of the chemical intermediate MPTP. 
PHYSIOLOGIC EFFECTS IN HUMANS 
In 1983, Langston and coworkers reported on 
four drug addicts who had been ingesting the 
synthetic heroin MPPP2• These addicts had been 
producing MPPP in a clandestine basement 
laboratory. Each subject presented with signs and 
symptoms remarkably similar to Parkinson ' s 
Disease (PD); the presentation of these subjects was 
thought to be due to contamination of drug samples 
with MPTP. In 1985, the same group reported on 
seven human cases of known MPTP-toxicity, in 
which each patient was diagnosed with clinically 
significant signs of the Parkinsonian state3• 
The subjects studied self-administered, by 
intravenous injection, MPPP in amounts ranging 
from 4.5 grams (g) over four days to 30 g over 20 
days. The frequency of administration ranged from 
3-10 injections per day3 • Biochemical, haematologic, 
urologic, radiologic, and neurologic studies were 
non-contributory in all subjects. Each subject 
manifested clinical symptoms with acute and 
chronic components. The following signs were 
associated with the acute component. Intravenous 
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administration resulted in a burning sensation in 
each subject. Subjects all felt typical heroin-like 
euphoria or dreaminess along with illusions, 
hallucinations, and blurred vision. Motor 
disturbances included sudden distal limb jerkiness 
and bradykinesia. Eventually, bradykinesia 
predominated and was accompanied by slow, 
dysarthric speech and intermittent resting tremor. 
Four of the seven subjects reported being "frozen" 
by three days post-administration. The chronic 
stage of MPTP neurotoxicity developed in days to 
weeks and consisted of most of the cardinal signs 
and symptoms of PD. These signs and symptoms 
included bradykinesia, rigidity, tremor, cog-
wheeling, micrographia, masked facies, widened 
palpebral fissures, glabellar sign, hypophonia, 
odynophagia, seborrhea, and diaphoresis3• 
Combination therapy of carbidopa/levidopa 
dramatically improved the extrapyramidal 
symptoms of most subjects. Symptoms, however, 
returned if therapy was discontinued . Moreover, 
increasing doses of carbidopa and levidopa were 
necessary to suppress clinical signs3• 
PHARMACOLOGICAL PARAMETERS 
After MPTP is administered to primates, it 
rapidly disappears from all tissues except the eye•, 
and produces no detectable basic, acidic, or neutral 
metabolites in organic extracts of biological tissues. 
Within one hour, large amounts of the highly water-
soluble 1-methyl-4-phenylpyridinium (MPP+) ion is 
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detectable in peripheral tissues and in the central 
nervous system (C S)4-6. In contrast to the rapid 
disappearance of MPTP, MPP+ (half-life, 48-100 
hours) is extremely long-lasting in the primate 
brain. Further, while MPP+ concentrations begin to 
decline in most brain regions and throughout the 
body between 24 and 72 hours after administration, 
MPP+ levels are actually increasing in the 
substantia nigra7 • Metabolism of MPTP to MPP+ 
takes place via a two-step oxidation process with 
the production of 1-methyl-4-phenyl-2,3-
dihydropyridinium (MPDP+) ion. Evidence 
suggests that this reaction is mediated primarily by 
monoamine oxidase (MAO)-Bs-12• This ion may be an 
important intermediary toward achieving 
significant CNS concentrations of MPP+. For 
example, some observations suggest that MPP+ 
does not cross the blood brain barrier (BBB) and 
must be injected directly into the C S 13- 15• This 
concept contradicts various animal models 
designed to study the effects of MPTP. These studies 
employ i. v. injections of MPTP. Perhaps i. v. 
injections result in significant CNS concentrations 
because MPTP is converted to MPDP+ which first 
crosses the BBB and is then converted into MPP+. 
NEUROTOXICOLOGIC PARAMETERS 
Injection of MPP+ into the striatum, medial 
forebrain bundle, or substantia nigra of rats resulted 
in marked striatal dopamine (DA) depletion 13-15• 
MPTP-induced dopamine depletion has also been 
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reported in mouse substantia nigra, nucleus 
accumbens, and olfactory tubercle3•16.17 . Although 
MPTP has been effective in producing dopamine 
depletion, actual neuronal cell loss has proved more 
difficult to produce. To date, primates remain the 
only animal that develops the major clinical signs of 
a full-blown and enduring extrapyramidal 
syndrome analogous to that seen in idiopathic PD18• 
MPTP causes similarly selective and extensive 
destruction of neurons of the substantia nigra par 
compacta (S pc) and the locus coeruleus in primate 
brain19• 
This species variability may exist because of the 
fact that whereas MPP+ disappears quickly from 
rodent brain, MPP+ is the predominant metabolite 
retained in primate brain for long periods. These 
differences may relate to inherent differences in 
response of cells to MPTP and its metabolites . 
Rodent liver and brain cells metabolize MPTP and 
MPP+ quickly; primate cells are much more 
sensitive to these toxins20• 
Other neurochemical changes which occur in 
primate brain tissue include reductions in acid 
metabolites of dopamine, norepinephrine, and 
serotonin in the medulla , pons, midbrain, 
hypothalamus, putamen, caudate, and frontal 
cortex21 • 
CLINICAL SIGNIFICANCE: 
THE LINK BETWEEN MPTP AND PD 
Parkinson ' s Disease is a neuropathological 
disorder characterized by degenerative changes in 
neurons in the S pc and consequential reductions 
in striatal DA content22 • In addition to the S pc, 
pathologic changes in idiopathic PD also include 
the locus coeruleus and the hypothalamus22• These 
brain regions also contain high densities of binding 
sites for MPTP23; this localization of binding sites 
establishes a potential link between MPTP 
neurotoxicity and idiopathic PD. Both conditions 
present clinically with akinesia, rigidity, and tremor. 
Pervading theories regarding causation of PD 
include genetic factors, C S aging, and foreign 
agents (microorganisms and toxins) . Barbeau and 
co-workers have suggested that the pathologic 
mechanisms of PD may be associated with 
exposure to environmental factors or endogenous 
toxins in genetically predisposed individuals 
subject to the normal processes of aging20• One such 
potential toxin is MPP+. 
The primary clinical relevance of MPTP is based 
on the accumulation of MPP+ in the S pc7·24 • 
Knowledge of this anatomic selectivity prompted 
investigators to utilize MPTP and MPP+ as 
substances which could induce clinically significant 
Parkinsonian symptoms in animal models . This 
resea rch w as expected to expand scienti fic 
understanding of the underlying neuropathologic 
mechanisms of MPTP-induced Parkinsonism and of 
idiopathic PD. Although a number of plausible 
theories have arisen to explain these mechanisms, 
the pathologic basis of PD or drug-induced 
Parkinsonism is still unknown. 
One theory which does have credence, however, 
relates to S iron stores. The "Iron Hypothesis" is 
based on the fact that basal ganglia structures are 
rich in iron25• In the presence of ferrous iron, MPTP 
forms superoxide ions and oxidizes DA26.v. Thus, 
basal ganglia iron stores may contribute to the 
mechanism of MPTP neurotoxicity. Iron stores also 
appear to play a role in idiopathic PD; autopsied 
brain tissue from patients with clinically diagnosed 
idiopathic PD revealed elevated concentrations of 
S iron26 • The putative role of iron in MPTP-
mediated neurotoxicity and in idiopathic PD 
provides indirect support for the theory that 
pyridine analogues are involved in the underlying 
pathology of PD. 
As well as being used to explain the pathologic 
basis of disease, animal models may also be used to 
screen drugs designed to treat disease. Murine and 
monkey models of PD have been employed for this 
purpose. Tatton and co-workers have utilized a 
murine model of MPTP-induced Parkinsonism to 
detect the value of drugs which slow progression of 
dopaminergic striatal neuronal degeneration27 • 
Research by this group has shown that the MAO 
inhibitor deprenyl prevents the death of toxically 
damaged neurons. The mechanism of action may 
not involve blockade of conversion of MPTP to 
MPP+. Another group has found that the MPTP 
monkey model is useful for predicting the potential 
value of new anti-Parkinson's drugs28• Levodopa, a 
DA agonist used to treat PD, frequently causes 
dyskinesia, the long term side effect of therapy. 
These researchers are using an MPTP monkey 
model to study the long term effects of potential 
anti-Parkinsonian drugs, with the hope that a drug 
will be found that does not produce dyskinesias. 
MDMA (N-METHYL-3,4-METHYLENEDIOXY-
AMPHETAMINE) 
MDMA is a methoxylated amphetamine base 
that was first synthesized in 1912. MDMA is 
derived from materials which contain a 
methlenedioxyphenyl ring, such as isosafrole, 
safrole, piperonal, and peiperonylactone. The D-
stereoisomer of MDMA is quantitatively more 
potent at exerting its effects than the L-isomer 29 • 
MDMA has many code names, including ecstasy, 
XTC, E, Adam, and Eve. This hallucinogen has 
been available on the illicit drug market since 1968. 
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The drug's popularity grew throughout the 1970's 
and 1980's and since the drug enforcement agency 
(OEA) placed MOMA on Schedule 1 of the 
Controlled Substance Act in 1985, MOMA has 
gained even more prominence30• 
PSYCHOLOGIC AND PHYSIOLOGIC EFFECTS 
Subjects taking MOMA report a sense of 
"closeness" in the first few hours after ingestion31 • 
Various physiologic effects also occur and include 
tachycardia, dry mouth, tremor, palpitations, 
diaphore is, parasthesias, trismus, and bruxism. 
Whereas many people report an increased 
alertness, many people also report a decreased 
ability to concentrate. A minority of subjects also 
report visual, but not auditory, hallucinations. 
These hallucinations tended to occur in the 
peripheral and not the central visual field 31 • 
Twenty four hours after ingestion, subjects 
tended to feel drowsy. This drowsiness is likely 
associated with the insomnia of the previous 24 
hours. Muscle aches, fatigue, depression, difficulty 
concentrating, and headache were also experienced. 
The worst subjective sensations however, were a 
sense of anxiety, worry, fear, and irritability 24-
hours post-ingestion31• About one half of MOMA 
users report that the positive effects of the drug 
diminished with repeated administration, whereas 
the negative effects tended to become more 
profound. 
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NEUROPHARMACOLOGY 
Rat brain regions affected by MOMA include the 
cerebral cortex, basal ganglia, septal area, thalamus, 
epithalamus, hypothalamus, hippocampus, and 
midbrain32• The pharmacologic profile of MDMA at 
various CNS receptor and uptake sites is: 5-HT 
uptake > alpha2 adrenergic = 5-HT2 = M1 
(muscarinic) = H1 (histaminic) > norepinephrine 
uptake= M2 = alpha1 adrenergic= beta adrenergic 
> OA uptake = 5-HT1 >> OA 02 > DA 0132. 
Studies of the effects of MOMA on rat brain shoed 
that the dopaminergic and serotonergic systems are 
significantly affected by MDMA. MOMA has been 
shown to decrease levels of tryptophan hydroxylase 
{TPH), serotonin (5-HT), and 5-hydroxy-indole 
acetic acid (5-HIAA) in several brain regions33.34 . As 
well, effects on serotonergic system are much more 
pronounced and longer lasting than on 
dopaminergic neurons35 • Dopamine appears to be 
crucial for MOMA to exert its effects on 
serotonergic neurons, since haloperidol blocks the 
effects of repeated doses of MDMA. Further, 
deinnervation of SN DA neurons with 6-hydroxy 
dopamine (6-0HDA) prevented the decrease in 
TPH levels in rat neostriatum compared with non-
treated brain regions such as the frontal cortex and 
hippocampus36• Finally, both DA and 5-HT uptake 
blockers (amfonelic acid and fluoxetine, 
respectively) also block MDMA-induced decreases 
in TPH levels37.38. 
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MDMA TOXICITY 
MDMA toxicity has been studied on a variety of 
animal models. For example, doses which cause 
death in 50% of subjects tested (LD50) range from 
32 mg/kg in rat, to 14 mg/kg in dogs, and 22 
mg/kg in monkey39. Lethal doses in man may only 
be inferred from various sources of literature, and 
the values vary. Levels near 1 J.Lg/ml have been 
associated with fatalities40, whereas levels as high 
as 7 J.Lg/ ml have no~1 • 
Therapeutic or recreational uptake of MDMA 
usually involves oral doses in the range of 75-100 
mg. At this level, a variety of side effects may occur 
which include tachycardia, tremor, facial muscle 
contracture, diaphoresis, nausea, vomiting, and 
bruxism. Disturbances become more severe as 
dosage is increased. Impaired cognitive, sensory, 
and motor skills have also been observed30.J1• 
Brain regions that suffer the greatest extent of 
MDMA-induced neurotoxicity also exhibit dramatic 
reductions in 5-HT uptake sites. For example, 
cortical regions that showed the most extensive 
destruction by autoradiographic analysis included 
the prefrontal, anterior cingulate, entorhinal, and 
parietal cortical regions32• These changes occurred as 
early as 18 hours after a four-day treatment regimen 
of 20 mg/kg MDMA (b.i.d.). The caudate-putamen 
regions, thalamus, and hippocampus also showed 
early degenerative changes32 • In the midbrain, 
regions with 5-HT projections (such as the terminals 
and axons of the SN) were more dramatically 
disturbed than regions with 5-HT uptake sites (i.e. 
perikarya) such as the raphe nucleus, central gray, 
ventral tegmental area, and pontine reticular 
formation32• 
The severity and extent of MDMA-induced 
lesions depend highly on the dose and frequency of 
administration. Neurotoxic effects may persist up to 
one year before structural recovery may occur; 
functional impairment can be permanent. 
Human deaths associated with MDMA may be 
direct or indirect. Direct deaths due to high doses 
may be due to overwhelming neurologic 
involvement, with a special risk for people with 
underlying cardiovascular disease. Indirect deaths, 
which seem to be more common, are likely due to the 
effects of cognitive, sensory, and motor impairment 
induced by MDMA-for example, a motor vehicle 
accident. As well, many people who have died with 
significant blood levels of MDMA have also had 
trace or significant blood levels of other drugs such 
as alcohol, cocaine, lysergic acid diethylamide (LSD), 
dextromethorphan, acetaminophen, and others. 
Thus, attributing death to MDMA is difficult not 
only on the basis of the effect of the drug itself, but 
also on the predisposition of the use~. 
CLINICAL USE OF MDMA 
MDMA was first used psychotherapeutically in 
the late 1970' s (before the drug was placed in 
Schedule 1 by the DEA) for patients who exhibited 
addictive behaviors. MDMA appeared to have the 
ability to assist the patient in surrendering his will 
to a "Higher Power" for personal guidance toward 
ultimate achievement of self-control. This attitude is 
thought to be critical in aiding the patient to gain 
release from previously destructive addictive 
behaviors, relations, and beliefs . One other 
important aspect in the therapeutic use of MDMA 
(and other psychedelic drugs) is the patient's 
understanding that the therapist has undergone 
MDMA training sessions and is capable of 
appreciating the subjective effects of the dru~. 
Patients who are acceptable candidates for 
MDMA psychotherapy should fulfill the following 
criteria: they should not have peripheral vascular 
or cardiovascular disease, they should not be on 
psychotropic medication, they should not h ave 
metabolic disturbances or liver disease, and they 
should not be pregnant~3 • Further, such patients 
should be relatively well-adjusted people with a 
willingness to solve their problems. 
The patient should also be instructed of all 
potential benefits and risks of the drug so that the 
patient may give informed consent for the session. 
The benefits include enhanced communication, 
introspection, and elevated mood . The 
physiological risks are associated with the 
sympathomimetic side effects of MDMA (bruxism, 
tachycardia, nausea, vomiting, hypertension) and 
with the potential5-HT depletion and neurotoxicity 
based on animal studies. The psychological side 
effects relate to the breakdown of the patient's 
defense mechanisms; the pain of incompletely 
reconciled grief or previous traumatic experiences 
may be felt both psychologically and somatically. 
Symptoms that may occur include psychologic 
depression and anxiety as well as headaches and 
dyspnea43• Side effects are not known to last beyond 
one to two days, whereas the duration of potential 
benefit from a successful session may be 
immeasurable. 
The entire therapeutic session may last may 
hours. After taking the drug, patients initially spend 
some time in isolation either in silence, meditation, 
or prayer waiting for the drug to take effect. 
Patients may continue to spend time alone in 
introspection once the drug begins to exert its 
effects. Once the patient feels confident with the 
individual issues and various physical signs, the 
patient is encouraged to confront these issues with 
the therapist. An additional 50 mg dose of MDMA 
may be offered to extend the effects of the drug. 
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Once the session is over and the drug effects begin 
to wear off, the patient may want to discuss the 
entire episode in eamest with the therapist43• 
Greer and Tolbert found that about 90% of 
patients had positive and beneficial experiences 
with MDMA44 • These researchers concluded, based 
on various clinical encounters, that MDMA serves 
to reduce emotional stress and fear associated with 
perceived threats to one's psychological integrity«. 
Exactly how MDMA achieves this loss of fear is 
unknown. Nonetheless, patients gain access to 
unresolved conflicts from childhood and other past 
relations and feel as though they have gained a 
broader, more complete understanding of 
themselves and their relations with others44 • 
Currently, psychotherapeutic applications of 
MDMA is legal only in Switzerland. Recent reports, 
however, suggest that the Food and Drug 
Administration (FDA) may lift the existing ban on 
research employing LSD and MDMA45 • The Swiss 
group of Widmer and colleagues use MDMA to 
study human consciousness47• Treatment of selected 
patients consists of two to four treatment sessions 
per year with MDMA or other psychoactive 
substances. Widmer's group have not observed any 
addictions MDMA. Further, addictions to alcohol, 
medical drugs, heroin, and other agents have been 
greatly reduced by MDMA-supported 
psychotherapy46. No evidence has accumulated to 
substantiate suspected CNS toxicity due to MDMA 
in the therapeutic dose range46• 
The current restriction on the therapeutic use of 
psychoactive substances suggests that these agents 
have not received the necessary scientific 
credentials to make this type of therapy acceptable. 
The lack of scientific support, coupled with negative 
social attitudes toward the use of psychoactive 
agents for medical treatment, make the likelihood of 
government-supported research a distant 
possibility. Only knowledge (gained from studies 
similar to those by Greer and Tolbert, and by 
Widmer et al.) may change this trend from rejection 
to acceptance. 
CONCLUSIO N 
Psychedelic drugs continue to be preferred 
agents among drug users to create altered states of 
mind. MPTP and MDMA are only two examples of 
a number of chemical compounds that have arisen 
as a result of psychedelic drug synthesis. Clearly, 
uncontrolled use of these agents can produce 
profound toxic effects in humans with disastrous 
results. In a controlled environment, however, each 
agent has a potential scientific benefit. Further 
research with MPTP may assist scientists not only to 
elucidate the underlying mechanisms of PD, but to 
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develop improved treatment modalities for this 
disease as well. Further, controlled therapeutic trials 
with MDMA may prove this agent to be a useful 
adjunct in the treatment of addictive disorders and 
psychological disturbances. 
The current surge in interest in MPIP, MDMA, 
and other such chemicals for the treatment and 
study of neurodegenerative, addictive, and 
psychological disorders suggests that hallucinogens 
and their byproducts will play an important role in 
the progression of scientific knowledge. 
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BUFOTENINE 
LICK I NG" 
AND THE 11 TOAD 
PHENOMENON: 
HISTORICAL PERSPECTIVES 
CURRENT T RENDS 
AND 
INTRODUCTION 
The ritual use of bufotenine as a hallucinogenic 
drug has long been practiced within some South 
American tribal cultures, but until recently, its use 
among North American drug users was virtually 
unknown. In the last few years, bufotenine has 
become the subject of media controversy when 
street-drug users were reported to have ingested 
bufotenine-containing toad venom for 
its alleged hallucinogenic effects; the 
media dubbed this practice "toad-
licking". These reports have revived 
interest in the hallucinogenic properties 
of bufotenine, but to date v ery few 
thorough accounts of the current toad 
l icking phenomenon ha v e been 
published. Although this curious 
practice is not likely to become a 
widespread drug abuse problem, it 
does merit a detailed examination. 
HISTORICAL PERSPECTIVES AND 
ETHNOPHARMACOLOGY 
Bufotenine is a hallucinogenic 
alkaloid found in several species of 
toads, plants and fungi. Bufotenine is the principal 
plant alkaloid from the seeds of Anadenanthera (Fig. 
1), a genus of leguminous trees consisting of the two 
species A. peregrina and A. colubrina . Tribal 
groups of South America use these species to 
prepare a hallucinogenic snuff powder which they 
consume. The earliest record of snuff prepared from 
A. peregrina is likely from 1496, when Europeans 
observed Taino Indians of Hispaniola self-
administering the snuff by nasal insuffla t ion 
through a long bamboo tube. This snu ff was 
reported to prod uce a rapid hallucinogenic effect 
and was primarily used in magicoreligious 
ceremonies19• Similar snuffs, called yopo, cohoba or 
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parica, made from the ground seeds of A. peregrina, 
were (and may still be) used by various tribal groups 
native to British Guyana, Brazil, and the Upper 
Orinoco Valley region of Venezuela and Colombia. 
The closely related species A. colubrina is found in 
the snuffs known as vilca or hulica in Southern Peru 
and Bolivia, and cebil in Northern Argentina. Each 
Indian tribe prepares the snuff in a slightly different 
manner but generally the seeds are toasted and 
Figure# 1 
ground into a powder which is 
mixed with lime from crushed 
snail shells or ash from the 
bark of certain trees. The 
powder is then sniffed through 
a tube made of wood or bird 
bone2. The alkaline plant ash 
and lime are thought to act not 
only as binding agents, but to 
facilitate the diffusion of 
alk aloids through the nasal 
mucosa as well. A typical 5 
gram dose of yopo snuff is 
taken up to three times a day 
and produces a rapid 
intoxication, of 15-120 minutes 
duration characterized b y 
initial stimulation, excitement, 
and hallucinations followed by 
a hypnotic or unconscious state. As well as 
bufotenine, Anadenanthera seeds also contain lesser 
amounts of two chemically related hallucinogenic 
alkaloids, dimethyl tryptamine (DMT) and 5-
methoxy-DMT, both of which may contribute to the 
hallucinogenic properties of Anadenanthera snuffs. 
In addtion to plant species, bufotenine is also 
contained in the toxic secretions of the cane toad 
(Bufo marinus) and the Colorado River or Sonoran 
desert toad (Bufo alvarius). The cane toad is found 
in South and Central America, the Southern United 
States, Puerto Rico, Hawaii, and Australia, In 
response to provocative stimuli, the toad secretes a 
milky white venom from the parotid gland s. This 
venom serves as a very effective natural defense 
against pred ators since, in addition to bufotenine, 
the toad venom also contains p otentially lethal 
quantities of digitalis-like cardiac glycosides 16 • 
Archaeological findings of large quantities of Bufo 
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skeletal remains from the ancient Olmec ceremonial 
site of San Lorenzo, Veracruz (1200-900 B.C.) 
suggest that the Olmec had knowledge of the 
properties of cane toad venom and may have used 
it as a "fortifier" in fermented ritual beverages19• 
Preparations of cane toad venom are still in use by a 
few indigenous tribal healers in Veracruz, Mexico, 
who use techniques passed down for generations to 
process and detoxify the venom, which is rolled into 
pills for later uses, for example, as an aphrodisiaCS. 
Along with plants and toads, bufotenine has 
been isolated from certain species of fungi. Small 
amounts of bufotenine have been found in 
hallucinogenic mushrooms of the genus Amanita1• 
The psychotropic properties of that species, 
however, are more likely due to the presence of the 
two principal alkaloids ibotenic acid and 
muscimoJ18• Interestingly, literary references have 
often associated mushrooms with toads, as for 
example the use of the word "toadstool" to describe 
certain toxic mushrooms. Similar chemical relations 
of certain hallucinogenic toad and mushroom 
species may have been known long before these 
associations could be validated scientifically. 
CHa 
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PHARMACOLOGY OF BUFOTENINE 
Bufotenine, also known as 5-hydroxy-N,N-
dimethyltryptamine (5-0H-DMT) and dimethyl 
serotonin, is a serotonin homologue which is 
closely related structurally to the hallucinogenic 
alkaloids DMT and 5-methoxy-DMT (Fig. 2). 
Bufotenine was first synthesized in the 1930's. 
Over two decades later, in 1956, the 
pharmacological effects of bufotenine in humans 
were first reported 4 • In a study by Faber and 
Hawkins, intravenous (IV) doses of bufotenine (4-
16mg) were administered to four inmates at the 
Ohio State Penitentiary. The subjects experienced 
dose-dependent psychological effects including 
vivid colour hallucinations, mental confusion, and 
feelings of euphoria and depersonalization. The 
physiologic effects noted were mydriasis, 
nystagmus, parasthesias, burning mouth, chest 
pain and dyspnea, nausea, vomiting,and purpling 
of the face and neck. The purple colour was 
described as "the approximate hue of an eggplant" 
and was thought to be due to serotonin-induced 
bronchiolar constriction and consequent 
hypoxemia. One subject's subjective experience 
with the drug was described in the following w ay: 
"He saw red spots passing before his eyes and red 
purple spots on the floor, and the floor seemed very 
close to his face. Within two minutes the visual 
phenomena were gone but they were replaced by a 
yellow haze". The psychologic effects, which are 
reminiscent of side effects caused by LSD and 
mescaline, developed rapidly and disappeared 
completely within 7-60 minutes, in a dose-
dependent fashion. A subsequent study reported 
similar effects from intramuscular (IM) injections of 
bufotenine at doses of 10-15 mg, but no observable 
effect was noted when bufotenine was giv en 
intranasally at a dose of 14 mg or orally at doses of 
up to 100 mg. The inefficiency of oral dosing is 
likely due to the extensive first-pass metabolism by 
monoamine oxidase3• Pharmacokinetic studies have 
found that IV bufotenine is very rapidly absorbed 
from the blood and excreted in the urine, 
predominantly (70%) in the form of the metabolite 
5-HIAA. Roughly 4% can be recovered from the 
urine in the unchanged form 11 • The toxicity of 
bufotenine in humans is not well known. Certain 
toxic responses, however, have been observed. An 
intra-muscular (IM) injection of 40 mg of 
bufotenine produced tachycardia, auricular 
fibrillations and extreme cyanosis in one patienflO 
and resulted in the development of card iac 
arrhythmias of the nature of multiple ectopic beats 
from supraventricular foci, at IV doses of 10-15 
mg3 • The pharmacological and toxicologic 
mechanisms underlying the behavioral effect of 
bufotenine have not yet been extensively studied, 
but there is evidence to suggest that its action as a 
partial agonist at serotonergic 5-HT2 receptors is 
involved 10• 
CURRENT TRENDS: "TOAD LICKING" 
For the past several years reports have 
circulated of a new trend in the use of bufotenine as 
a street drug - in the form of "toad licking" - the 
practice of ingesting the hallucinogenic secretions 
of the cane toad. This bizarre new practice caused 
something of a media sensation; exaggerated 
accounts of toad licking appeared in news reports 
throughout North America where toad licking was 
often referred to as the "latest fad" . Media attention 
to the toad licking phenomenon seems to have 
begun shortly after the release of a critically 
acclaimed 1987 comic documentary Cane Toads by 
Australian film-maker Mark Lewis. The film dealt 
with the colourful history of the cane toad in 
Australia and alluded to the possibilities of 
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ingesting toad venom for its hallucinogenic effect. 
Both the film and toad-licking received major press 
coverage in newspapers and magazines throughout 
orth America, with articles appearing in 
ewsweek 24, The ew York Times 9, Scientific 
American8, Smithsonian13 and Medical Pose1, and 
various local newspapers. Doubt exists as to 
whether toad licking was ever practiced among 
North American drug users prior to the media 
reports that drew attention to the hallucinogenic 
possibilities of toad venom. Contrary to what the 
sheer volume of reports would indicate, toad 
licking is still a rare occurrence. At least four 
incidents of deliberate toad venom ingestion have 
been documented, all of which resulted in 
hospitalization. In New Mexico, two teenagers 
ingested cane toad venom after reading news 
reports of the "fad", and had to be hospitalized8 • 
Further, in Australia, deaths have been reported as 
a result of ingesting cane toad eggs 13 and after 
drinking tea brewed from cane toad venom23 • 
Media publicity was again an instigating factor 
when two Toronto men, aged 28 and 31, ingested 
cane toad secretions within a few days after 
watching a CBC-TV screening of Lewis' film Cane 
Toads6.14·15• One of the two men had to be treated in 
the intensive care unit at North York General 
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Hospital for seizures. One of the most thoroughly 
documented cases of intentional cane toad venom 
ingestion was reported by a pediatrician who 
treated a 10 year old boy admitted to the 
emergency ward at a Florida hospitaJ1 7 • Upon 
admission, the boy was experiencing acute 
episodes of incoherence and complained of severe 
headaches and hallucinations. Electrocardiographic 
findings revealed secondary atrioventricular block 
(type I). No other clinical findings were sigrtificant. 
The boy was given i.v. fluids and monitored 
overnight. The next day both his behavior and 
electrocardiogram had returned to normal and he 
later admitted that he and his friends had been 
licking cane toads for the purpose of "acting 
crazy". 
The most prominent clinical features of cane 
toad poisoning consist of profound drooling, 
seizure activity, arrhythmias, and cyanosis. 
Treatment for bufotenine intoxication is based upon 
supportive and symptomatic measures. 
Recommended drug therapy can include activated 
charcoal, hydrocortisone sodium succinate for 
respiratory complications, phenobarbital to control 
seizure activity, phenoxybenzamine (an a-receptor 
blocker) to relieve hypertension, and propranolol (a 
B-blocker) to reverse cardiac arrhythmiasl2,7. 
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LEGAL STATUS 
Bufotenine is not available by prescription 
anywhere in the world nor does there appear to be 
an illicit market for the synthesized drug. In the 
United States bufotenine is covered under Schedule 
I of the Controlled Substances Act (the same 
schedule that covers highly addictive drugs such as 
cocaine and heroin) since there is the potential for 
abuse and no known medical uses for bufotenine. 
Rumours about a bill to ban toad licking in Georgia 
were later reported to be false23, but other sources 
mention that such a bill is under consideration in 
South Carolina17• The government of Queensland, 
Australia has restricted the use of Bufo secretions by 
classifying them as dangerous substances under its 
Drug Misuse Act22 • In Canada, toad-licking is not 
illegal, according to a quote from a Toronto police 
constable, and cane toads are sold legally at several 
pet stores15• 
CONCLUSIONS 
Ingestion of toad venom and bufotenine is still a 
relatively rare and isolated occurrence among orth 
American street-drug users. However, with 
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results. 
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continued media attention to the hallucinogenic 
possibilities of these agents, further incidents 
involving cane toads or other bufotenine containing 
substances may be anticipated. Considering the 
likelihood of serious injury as a consequence of toad 
venom ingestion, medical clinicians should be 
aware of this phenomenon and attempt to monitor 
the emergence of this drug abuse trend in the 
future. 
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RESEARCH 
THE HOASCA PROJECT: 
PROPOSAL FOR A BIOMEDICAL 
INVESTIGATION OF AYAHUASCA 
Dennis J. McKenna, Ph.D. 
Ayahuasca is a Quechua term meaning "vine of the souls," and is one of the numerous indigenous names for the hallucinogenic 
drink prepared from a combination of two 
Amazonian plants, Banisteriopsis caapi, and 
Psychotria viridis. In Amazonian Peru and parts of 
Colombia and Ecuador, the drink is known as 
ayahuasca; in other parts of the Amazon, it is 
known as yage, natema, or pilde; in Brazil, it is 
known as hoasca, or sometimes simply "the tea." In 
whatever cultural context it is found, and by 
whatever name, ayahuasca plays a pivotal role both 
in the spiritual life of the populations that use it, 
and in local ethnomedical practices. The drink is 
regarded as both a sacrament, and a medicine. For 
the shamans familiar with its properties, it is both a 
diagnostic aid and a respected teacher; for the pa-
tients who seek the healing the shamans can offer, it 
is the ideal holistic medicine, providing the means 
to cleanse and heal both the mind and the body. 
From the perspective of modern psy-
chopharmacology, practically nothing is known of 
how it actually affects the human mind/body. 
Recently, a unique opportunity has become 
available to carry out a biomedical investigation of 
the immediate and long-term effects of ayahuasca in 
human users. This opportunity has resulted from 
recent friendships established by the author with 
members of a Brazilian organization, the Unao do 
Vegetal (UDV) which is essentially a syncretic 
religious movement in which the collective, 
periodic ingestion of hoasca tea is the central 
ceremony and sacrament. Unlike the more 
traditional use of ayahuasca in the context of 
mestizo or aboriginal shamanism, the use of hoasca 
tea within the UDV is strictly regarded as a 
religious or spiritual practice (as opposed to a 
curing or medical practice). Moreover, many of the 
younger adherents to the UDV "cult" tend to be 
well-educated urban professionals. Some of the 
members are Western-trained physicians, 
psychiatrists, or o ther h ealth professionals who 
frequently possess a solid training in medical 
These articltes were reprinted with the kind permission of Rick Doh/in, 
president of MAPS. (See page 38.) 
disciplines and a healthy scientific curiosity about 
the physical and psychological effects of hoasca tea. 
They understand as much as anyone does about the 
active alkaloids found in hoasca tea, and about its 
putative mechanism of action. Many of these 
individuals would like to learn all that can be 
learned about how it works, but at the same time 
they maintain a sense of reverence regarding their 
sacrament; they consider that an effort to un-
derstand hoasca using the tools and paradigms of 
science is not a sacrilege if it is pursued as part of a 
sincere effort to increase our know ledge of this 
remarkable medicine. 
This enlightened attitude establishes an intellec-
tual climate in which a pharmacological and psy-
chological investigation of hoasca could be carried 
out if the required resources were available. While 
attending a conference on the biomedical aspects of 
hoasca which was hosted by the UDV in Sao Paulo 
in June, 1991, I made a proposal for a biomedical 
investigation of the human pharmacology of hoasca 
to some of the leaders of the UDV. The response 
was more than receptive, it was enthusiastic. Since 
this conference, we have remained in frequent 
contact, and have continued to work together on 
developing a proposal setting forth the objectives 
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and methodologies for a pilot study on the action of 
hoasca in humans. 
As currently conceived, a number of parameters 
related to the psychophysiological effects of hoasca 
will be investigated, among them the following: 
Composition of hoasca teas. The UDV recog-
nizes several kinds of hoasca, which differ in their 
modes of preparation and in their effects. The 
composition and amount of active alkaloids in these 
various types of tea will be analyzed and compared. 
Acute pharmacokinetics of hoasca. Pharmaco-
kinetics is the study of the absorption, metabolism, 
and excretion of drugs. The phar-macokinetics of 
the major alkaloids of hoasca (harmine and DMT) 
will be determined in blood samples taken from 
volunteers using a technique known as gas 
chromatography /mass spectrometry (GC/MS). 
Acute/long-term effects of hoasca on seroton-
ergic functions. Hoasca, like other hal-lucinogens, 
is known to interact primarily with receptors for the 
neurotransmitter serotonin (5-HT, 5-
hydroxytryptamine). The effects of hoasca on 
serotonergic functions can be determined in blood 
and plasma samples by analyzing various parame-
ters, such as the levels of hormones known to be 
modulated by the serotonin system (e.g. prolactin, 
ACTH, beta-endorphin) . In addition, blood 
platelets contain many of the same serotonin 
receptors that are found in the brain, and 
psychopharmacologists have long used platelet re-
ceptor binding assays as a peripheral marker for 
changes presumably occurring in the central ner-
vous system. We propose to use platelets to monitor 
the effects of hoasca on certain serotonin receptor 
subtypes, and also to measure peripheral 
monoamine oxidase (MAO) inhibition. These pa-
rameters will be measured in volunteers drawn 
from the members of the UDV before and after the 
ingestion of known doses of hoasca tea. 
In addition, a parallel study will investigate the 
possible long-term effects of hoasca by examining 
these parameters in a group of older maestres -
members of the UDV who have taken hoasca 
regularly for much of their adult lives.This group of 
maestres will be compared with a set of age-matched 
control volunteers who have not taken hoasca. 
These are the primary objectives of the initial 
study. Additional parameters may also be mea-
sured, such as the effect of hoasca on immune 
functions, or its effect on cognitive function as 
measured by psychological and cognitive assess-
ment procedures. 
[Editor's note: At the time this article was 
reprinted, the required $50 000 to commence 
research was already acquired. ] 
IBOGAINE UPDATE 
by Bob Sisko 
Last year, the Medications Development Division (MOD) of the National Institute on Drug Abuse (NIDA) began a research 
initiative to evaluate the use of ibogaine as an anti-
addiction agent. Since than, numerous articles have 
appeared in scientific journals, both in the US and 
abroad, which show promising results. 
Spearheading the research efforts are the 
Pharmacology and Toxicology Department of 
Albany Medical collefe, headed by Dr. Stanley D. 
Glick. His department published no fewer than six 
papers in little over a year. Other New york 
research institutions evaluating ibogaine include the 
Nathan S. Kline Institute for Psychiatric Research, a 
facility of the New York State Office of Mental 
Health affiliated with NYU Medical Center, and the 
City University of New York Medical School. 
Claims that ibogaine is effective as atreatment 
for both cocaine and opiate narcotics were at first 
widely viewed with skepticism. Cocaine is, after 
all, a stimulant while opiate narcotics have an 
oposite effect, that of sedating the user. What they 
do share in common, however, is that use of either 
substance increases dopaminergic (DA) activity in 
the brain's mesolimbic system, and/or mesocortical 
pathways. This triggers the reward mechanism, 
which is associated with the reinforcing effects of 
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drugs of abuse. Researchers thus began looking at 
the relationship of ibogaine to the DA system. 
In early 1991, Dr. Broderick of CUNY Medical 
School submitted an abstract to the College on 
Problems of Drug Dependence (CPDD), The African 
Alkaloid, Ibogaine, Alters Cocaine-Induced 
Accumbens Dopamine Neurotransmission: In Vivo 
Voltametric Studies in the Conscious Brain. She 
reported that ibogaine reduced cocaine induced DA 
increases, but without complete depletion, and 
observed, "These data have clinical implications 
because pharmacotherapeutic medications which 
decrease DA neu-
rotansmission 
without a complete 
DA block could 
dirdumvent the 
reported anhedonia 
often associated 
with some cocaine 
treatment moda-
lities." Her final 
report, presented at 
the CPDD' s 53rd 
annual scientific 
Ibogaine 
meeting, concludes, "Thus, ibogaine's effects are 
consistent with current views regarding rational 
strategies for cocaine treatment."1 
At the same time, researchers at the Division of 
eurochemistry at the Nathan Kline Institute in 
Orangeburg, NY were examining the relationship 
between ibogaine and cocaine in mice. Henry 
Sershen, et,al., reported this year tha' Ibogaine 
Antagonizes Cocaine-Induced Locomotor 
Stimulation in Mice2 • "The results," he states, 
"suggest that ibogaine may have induced a selective 
change in the dopaminergic system that results in a 
decrease in responsiveness to cocaine that persisted 
for at least one week." He further concluded that 
" The above results are not in conflict with the 
proposed uses of ibogaine in the treatment of 
cocaine abuse, since increased dopamine 
neurotransmission has been shown to be associated 
with the locomotor-stimulant and reinforcing effects 
of cocaine. Attenuation of the e effects by ibogaine 
could possibly reduce the craving for cocaine." 
Additional work involving ibogaine and cocaine 
was accomplished by m.R. Dzolic, of Erasmus 
University in Rotterdam. An abstract submitted to 
the CPDD, Effects of Ibogaine on Cocaine Self-
Administration in Rats, showed promising results, 
and compared favorably to uncontrolled clinical 
observations. "All this is encouraging," said Dzolic, 
"s ince it supports the idea that ibogaine is a 
potential long lasting interrupter of both cocaine 
and morphine dependency." 
In June, 1992, Dzolic made and oral presentation 
F eature Sect i o n 
to the CPDD at the 54th annual scientific meeting in 
Keystone, Colorado. The significance of his 
findings are twofold. Firstly, heretofore the 
interruption of cocaine self-administration with a 
non-toxic substance was unheard of. In a number of 
widely-reported studies, animals, when given the 
ability to self-administer cocaine did so 
continuously, ignoring food, water, and sex until 
they died. Secondly, Dzolic's findings are consistent 
with those of S.D. Glick, et.al., Effects and 
Aftereffects of Ibogaine on Morphine Self-
Administration in Rats.3 
Glick found that not only would 
ibogaine interrupt morphine self-
administration, but that it continued to do 
so long after the ibogaine was eliminated 
from the body. Citing two US patents 
(4,499,096; 4,587,243) which describe the 
potential effecacy of ibogaine in treating 
opeate and cocaine addiction, Glick 
concludes, "Though far from addressing the 
full extent of the claims presented in the 
patents, the results of this study suggest that 
such claims should be taken seriously, and 
that further investigation is warranted." 
In a study entitled, Interactions between 
Ibogaine, a Potential Anti-Addictive Agent, and 
Morphine: An In Vivo Microdialysis Study• I.M. 
Maisonneuve et.al. found that "It appears that 
ibogaine affects brain DA systems for a period of 
time that exceeds its elimination from the body, and 
during this time, alters the responses of these 
systems to morphine. By preventing the increase in 
dopaminergic transmission induced by morphine in 
the nucleus accumbens, ibogaine may decrease the 
reinforcing efficacy of morphine. Thus, although a 
definitive mechanism underlying the claims 
regarding ibogaine's therapeutic effects cannot be 
specified yet, the results of the preesnt study 
indicate that such mechanissms merit 
investigation." 
Maisonneuve and Glick published two other 
papers addressing the dopamine question, 
Interactions between Ibogaine and Cocaine in Rats: 
An In Vivo Microdialysis and Motor Behavio~; and 
Acute and Prolonged Effects of Ibogaine on Brain 
Dopamine Metabolism and Morphine-Induced 
Locomotor Activity'. 
Glick then turned his attention to another claim; 
the claim that ibogaine will suppress the multiple 
symptoms of narcotic withdrawal. The claim that 
ibogaine attenuated many, but not all, symptoms of 
withdrawal was first reported by Djolic et.al., Effect 
of Ibogaine on Naloxone-Precipitated Withdrawal of 
Chronic Morphine Dependent Rats7 Two years later, 
Aceto, Bowman and Harris at the Medical College of 
Virginia reported that ibogaine suppressed 
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withdrawal signs in morphine dependent monkeys8• 
A controversy was created when Sharpe and Jaffe 
refuted those findings, stating that ibogaine failed to 
reduce the majority of withdrawal in morphine 
d ependent r a ts . Howev er, Sharpe and Jaffe 
conceded that such discrepancies were possibly the 
result of methodological d ifferences . "Despite all 
these differences," observed Glick, "some aspect of 
the opiate withdrawal symptom was ameliorated in 
all three studies." 
G lick prepared a s tudy to re-examin e the 
possibility that ibogaine might attenuate morphine 
withdrawal. His res ults indica te that ibogaine 
s ignificantly decreased the intensity o f many 
withdrawal signs9• "Exactly how ibogaine might 
attenuate opiate witdrawal is, at this point, open to 
conjecture, " Glick s tates . "Regardless o f the 
explanation," he concludes, " the present results 
indicate that the potential usefulness of ibogaine in 
treating acute manifestations of opioid depen dence 
should be further investigated." 
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THE CARDIOVASCULAR AND 
NEUROLOGICAL EFFECTS OF 
COCAINE TOXICITY 
Anne Silas, Meds 94 & Rocco Gerace, M.D. 
ABSTRACT 
The widespread use of cocaine has led to an increase in Emergency Department admissions for treatment of the acute toxic effects of this drug. Recently, an increase in fatalities has been ascribed to its cardiovascular and neurologic complications1 • These include acute myocardial injury, 
arrhythmias, stroke, seizure, and death2• Recognition of the cocaine abuser's presentation in the ED, and 
knowledge of the various applicable treatments, may reduce mortality and morbidity associated with 
cocaine intoxication. 
INTRODUCTION 
Cocaine is a naturally occurring alkaloid of the 
Coca plant Erythoxylun coca which is found 
throughout the Andes mountains. The use of 
cocaine dates back at least 5000 years among the 
Incas3• However in Europe, cocaine did not become 
popular until the 1860s when the active ingredient 
benzoy ' methylecgonine hydrochloride, was 
isolated4 • Prior to this time, the loss of potency 
during transport greatly suppressed the popularity 
of the coca plant. 
In the past decade, the widespread use of 
cocaine has led to an increase in emergency 
department admissions for treatment of its acute 
toxic effectsl. These effects include agitated 
delirium, seizure and stroke2, myocardial ischemia 
and infarction5.6, as well as tachyarrhythmias and 
myocarditis7• Episodes of silent myocardial ischemia 
have also been noted during the first weeks of 
cocaine withdrawal8• 
Although the relationship between cocaine 
toxicity and We-threatening cardiac events has been 
recognized historically as tempora 16, documentation 
of cocaine-induced coronary vasoconstriction has 
suggested this relationship to be causa17 • Several 
mechanisms, however, have been proposed to 
explain cardiovascular complications subsequent to 
cocaine intoxication. These include, in addition to 
coronary artery spasm, focal coronary 
vasoconstriction9, thrombus formation and platelet 
aggregation 10, direct myocardial toxicity 11 , and 
increased myocardial oxygen demand7• 
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PHARMACOKINETICS 
An understanding of the pharmacologic and 
toxicologic characteristics of cocaine is helpful in 
understanding clinical toxicity. 
There are a variety of forms of cocaine that 
allow self administration. For example, cocaine 
hydrochloride, a white crystalline powder, is highly 
water soluble and administered intravenously or by 
nasal insufflation. Cocaine hydrochloride may be 
converted to the free-base form by dissolving the 
powder in an alkaline solution, using a solvent 
such as ether to extract the cocaine, and finally, 
evaporating the solvent. Crack is a form of free-
base made using baking soda and water4 • The free-
base form of cocaine HCl vaporizes at temperatures 
greater than 98C without being destroyed, thereby 
allowing it to be smoked. Clinical effects associated 
with rapid absorption and ease of administration of 
free-base form was led to the popularity of 
smokable crack cocaine. 
The pharmacokinetics of cocaine vary with the 
mode of administration of the drug. Cocaine is 
absorbed from various sites in the body including 
mucous membranes and the gastrointestinal tract. 
Following intranasal administration, the drug 
begins to exert its effects in about twenty minutes. 
The drug's half life may be several hours due to 
continued absorption. Smoking cocaine results in 
almost immediate pulmonary absorption and 
rapidly increasing blood concentration levels. 
Cocaine is rapidly and extensively metabolized by 
plasma and liver cholinesterases to the water 
soluble metabolites ecgonine methyl ester and 
benzoylecgonine'0• 
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Once cocaine is absorbed, it produces its 
effects through local membrane stabilizing and 
sympathomimetic actions 10• The primary target 
sites for the effects of cocaine include 
cardiovascular and neural tissues 12• Initially, on 
the basis of central dopaminergic stimulation, 
cocaine produces euphoria and excitement, as well 
as an increase in heart rate and arterial blood 
pressure and in severe cases, arrhythmias and/ or 
coma. This intense stimulation may be followed 
by anxiety, paranoia, and depression of 
respiration. 
Cocaine has sympathomimetic as well as 
anaesthetic properties. By inhibiting sodium 
conductance, cocaine inhibits nerve impulse 
conduction. Cocaine also produces increased 
peripheral catecholamine levels by preventing 
presynaptic reuptake of neurotransmitters 12 • 
Cocaine's ability to directly stimulate central 
vasomotor centres compounds this drug's 
potential to create intense sympathetic 
stimulation. Small vessel vasoconstriction, 
increased vascular resistance, and increased 
cardiac output are among the drug's pathologic 
cardiovascular effects 13• 
TOXICOLOGY 
Although toxic effects of cocaine may be 
manifest in a variety of organ systems, including 
cardiovascular, neurologic, peripheral vascular, 
gastrointestinal, and musculoskeletal, the CNS 
and cardiovascular systems are responsible for 
most of the life-threatening complications seen. 
Specific neurologic complications include agitated 
delirium (intense paranoia) 14, cerebrovascular 
accident (potentially involving cerebral infarction, 
in tracerebral hemorrhage, or subarachnoid 
hemorrhage) 15, and partial or generalized tonic-
clonic seizures16 • Seizures have been suggested as 
the single most lethal effect of cocaine toxicityt7• 
Death in relation to cardiovascular complications, 
can result from ventricular fibrillation or asystole 
following doses as little as 20mg of parenterally 
administered cocaine. Recently, an increase in 
fatalities has been ascribed to cardiovascular and 
neurologic complications•. 
Blood levels of cocaine can be misleading. A 
200-fold range of levels have been reported as 
lethal 11 • This is explainable given that 
susceptibility to the drug's toxic effects, as well as 
i t s metabolism, varies among individuals 18 • 
Therefore, cardiac and neurologic consequences, 
however, are not limited to large doses of cocaine6• 
CARDIOTOXIC EFFECTS O F COCAINE 
Cocaine's cardiotoxic effects can result from all 
modes of administration of the drug6. Further, 
underlying heart disease is not a requisite for 
cocaine cardiotoxicity19• Stimulation of the central 
vasomotor centres and rising levels of peripheral 
catecholamines produce hypertension and 
tachycardia, as well as an initial increase in blood 
pressure. The drug's direct toxic effects on the 
myocardium may subsequently produce a fall in 
blood pressure. The sudden increase in myocardial 
oxygen demand, produced by an elevated heart rate 
and increased systemic arterial pressure, coupled 
with vasoconstriction of coronary blood ve sels and 
resulting decreased oxygen supply, may override 
coronary autoregulation and produce the 
cardiovascular toxic effects associated with this 
drug7• 
Other potential theories that may explain the 
cardiotoxic mechanisms of cocaine in addition to 
acute myocardial infarction, coronary 
vasoconstriction, and arrhythmias, include platelet 
aggregation 10•19, contraction band necrosis 4•20, 
myocarditis2.4, and cardiomyopathy (see figure 1}10.21• 
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Figure 1 
ACUTE MYOCARDIAL INFARCTION 
The etiology of acute myocardial InJury is 
multifactoria1• Cocaine's sympathomimetic effects 
elicit an increase in myocardial work. Coupled with 
a decrease in myocardial blood flow produced by 
coronary vasoconstriction and impaired pump 
activity, these toxic effects contribute to ischemia 
and perhaps, infarction. The combination of direct 
toxic effects of contraction bands and platelet 
adhesiveness, predispose to focal myocardial injury 
and, in the long-term, cardiomyopathy 21 • 
Furthermore cocaine may directly depress 
ventricular function in the absence of any acute 
myocardial injury. Acute ventricular dysfunction 
may occur as a result of sodium channel blockade. 
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MEDICAL VOCABULARY 
This section is designed to test and expand your knowledge of medical 
terminology. How many items can you correctly define? 
Scoring: [13-lS]=Superior knowledge, [10-12]=Abo e average, [8-9]=Adequate, [S-7]=Fair, [1-4]=Sub-par. 
1. Degloving: 
a) debridement of the palmar epidermal layer 
following burn injury; 
b) intra-oral surgical exposure of the bony 
mandibular regions; 
c) removal of procedure gloves following 
contamination of the surgical field; 
d ) post-operative anaesthesia! phenomenon 
involving transient parasthesia of the upper 
limbs; 
2. Xenophonia: 
a) alteration in the quality of voice; 
b) the adoption of a foreign voice due to 
schizophrenic delusions; 
c) the quality of sound produced by a non-native 
speaker of a language; 
d ) the auditory hallucination of a non-self voice 
evident in schizophrenia; 
3. Zonesthesia: 
a) a loss of feeling or sensation involving multiple 
derma tomes; 
b) area of focal numbness caused by local 
anaesthetic; 
c) a zone characterized by swelling and loss of 
function caused by a zootoxin; 
d ) a sensation of constriction , as by a girdle; 
4. Miliary: 
a) a form of hyperkeratinized epithelial cyst; 
b) pertaining to a cutaneous condition with 
retention of sweat; 
c) characterized by lesions resembling millet 
eeds; 
d ) a erythemic sign; 
5. Butyroid: 
a) trademark for a preparation of butacaine 
sulfate; 
b) an amino acid derivative of butyric acid; 
c) an abnormal amount of saturated fatty acid 
residues in sweat due to chemical imbalance of 
the body; 
d ) resembling or having the consistency of butter; 
6. Transfaunation: 
a) genetic transformation in viruses; 
b) genetic recombination of non-host D A with 
host D A; 
c) transfer of animal parasites from one host to 
another; 
d) Old English term for transformation; 
7. Viraginity: 
a) p eudohermaphrodi m resulting in an inability 
to conceive; 
b) a consequence of androgenization syndromes; 
c) incapable of inducing o ulation; 
d) a condition in which a woman has the sexual 
feelings and mentality of a man; 
8. Perionyx: 
a) a relic of the eponychium persisting as a band 
across the root of the nail during fetal 
development; 
b) situa ted about the nailbed; 
c) a kind of hypopyon; 
d) an activating area associa ted with the dorsad 
region of the embryonic notochord; 
9. Bubo: 
a) a dome-shaped skin lesion with transient 
surface vesiculations; 
b) inflamed lymph node, particularly in the groin 
or axilla; 
c) the non-muscular component of the 
bulbococcygeus muscle; 
d) a disease caused by consumption of the 
poisonous fruit of a tropical vine; 
10. Fleckfeiber: 
a) epidemic typhus; 
b) intrinsic "trigger" to regulate diurnal rhythm; 
c) a German department store; 
d) a syndrome associated with a virulent pathogen 
of unknown origin; 
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11. 
a) 
b) 
c) 
d) 
12. 
a) 
b) 
c) 
d) 
Fragiform: 
disruption of Haversian canal formation in 
bone; 
shaped like a strawberry; 
general description of any friable lesion; 
none of the above; 
Stomatomalacia: 
any pathological condition of the mouth; 
softening of tissue of the abdominal wall 
surrounding a colostomy /ileostomy opening; 
a condition of body weakness; 
abnormal softness of the oral structures; 
13. Trichonodosis: 
a) a fungal infection caused by species of 
Trichophyton; 
b) the condition in which hairs are split and 
feather-like; 
c) knotting of the hair as a result of inability of 
new hairs to grow from their follicles; 
d) any disease or abnormal growth of the hair; 
14. Meroacrania: 
a) partly secreting; 
b) a teratogenic consequence of organic mercury 
exposure; 
c) partial congenital fissure of the cranium which 
extends into the cervical vertebrae; 
d) congenital absence of part of the cranium; 
15. Fourniere's Gangrene: 
a) necrosis of a digit secondary to the use of 
epinephrine in a local anaesthetic preparation; 
b) fulminating gangrene of the scrotum; 
c) tracking of anaerobes fran a bite wound in the 
hand; 
d) gradual onset psychosis secondary to sle p 
deprivation; 
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Would you like more experience in general 
medicine, particularly in the management of 
patients with cancer? 
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Cancer Centre , and Medical Oncology Unit, St. 
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3 clinical assistants, 2 medical oncology residents, and 
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ANSWERS TO MEDICAL VOCABULARY 
1. Degloving: 
b) The exposure of the bony mandibular anterior or 
posterior regions by oral surgery. 
2. Xenophonia: 
a) Alteration of the accent and intonation of a 
person's speech. 
3. Zonesthesia: 
d) A painful sensation of constriction, as of a 
bandage bound too tightly, especially around the 
waist, also known as girdle sensation. 
4. Miliary: 
c) Characterized by lesions resembling millet 
seeds, as in miliary tuberculosis. 
5. Butyroid: 
d) Resembling or having the consistency of butter. 
Butyric acid is a four-carbon fatty acid found in 
rancid butter. 
6. Transfaunation: 
c) Transfer of animal parasites from one host to 
another. 
7. Viraginity: 
d) A condition in which a woman has the sexual 
feelings and mentality of a man. 
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8. Perionyx: 
a) A relic of the eponychium persisting as a band 
across the root of the nail, seen in the eighth month 
of fetal life. 
9. Bubo: 
b) An enlarged and inflamed lymph node, 
particularly in the groin or axilla, due to an 
infection such as plague, syphillis, gonorrhoea, 
lymphogranuloma venereum, and tuberculosis. 
10. Fleckfeiber: 
a) Epidemic typhus. 
11. Fragiform: 
b) Shaped like a strawberry [L. fraga, strawberry]. 
12. Stomatomalacia: 
d) Abnormal softening of the oral structures. 
13. Trichonodosis: 
c) A rare condition characterized by apparent or 
actual knotting of the hair thought to be the result 
of inability of new hairs to grow freely from their 
follicles because of abnormal toughness of the 
surrounding tissues. 
14. Meroacrania: 
d) A congenital absence of part of the cranium. 
15. Fourniere's Gangrene: 
b) Fulminating gangrene of the scrotum. 
With the compliments of 
~ MARION MERRELL DOW 
~ I CANADA 
(Marion Merrell Dow Canada) 
2150 St. Elzear Blvd. W. 
Laval , Quebec H7L 4A8 
U.W.O. Medical Journal 62 (1) 1992------------------------ 49 
P r ob l em So lvi ng 
ANSWERS TO CASE STUDY 
1. Was there any blood in the erne is or diarrhea? 
ot in his emesis; he did not look at the diarrhea. 
Did anyone el e eat the mushrooms? His wife only 
had a teaspoonful full. (She was worried they were 
not safe.) She has had a small amount of diarrhes 
and has thrown up twice. 
2. He has not kept anything down for 12 hours 
and is dehydrated. Start an IV and give him some 
normal saline. It would be kind to also give him 
some Gravol for the nausea. Because mushrooms 
can cause renal and hepatic failure you need to do 
some routine blood work including renal and liver 
function tests and a PT / PTT. 
3. Who knows. You would expect him to be 
hypokalemic from all the diarrhea. Perhaps it was 
from damaged liver cells. He need an EKG (look 
for peaked T waves) and gases done. He is at risk 
of going into v.fib unless his K promptly lowered 
by driving it back into cells (gi e dextro e and 
insulin, and bicarb) and by eliminating it (with an 
ion-exchange resin such as Kayexalate). 
4. Very worried. There are several different 
groups of mushrooms. The clinical effect vary 
with the type of toxin ingested. Con idering he got 
sick more than 6 hours after he ate the mushrooms, 
the se erity of the vomiting and diarrhes and that 
his AST is already up, he probably ate Amanita sp. 
Poisoning wi th this type of mushroom has a 
mortality of 20-30%! 
When words fail ... 
Medic Alert. won't. 
CanMflan Medic Alert" Foundlltlon 
Box9800 
Don Mills, Ontario M3C !n'9 
(416)~7 
1-«10-661-1507 
The following misconceptions in the treatment 
of mushroom poisoning should be avoided. 
1) Poisoning may be an allergic reaction or food 
poisoning secondary to bacteria; 
2) Poisoning may be secondary to pesticides 
sprayed on the mushroom or to edible mushrooms 
laced with drugs (like PCP); 
3) All people ingesting mushrooms must become 
ill· I 
4) Symptoms presenting after six hours can' t be 
due to Amanitas ingestion; 
5) Di charge of patients without follow-up despite 
reco ery from GI symptoms when the e symptoms 
occurred six hours post-ingestion; 
6) As e sing toxin identification and considering 
antidotes take precedence over theorie s of 
supportive care; 
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